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ABSTRACT 
 
Spasticity and rigidity are two common types of abnormal muscle behavior seen among 
patients with neurological disorders (e.g., stroke, Parkinson’s Disease). Clinical assessment of 
increased muscle resistance during passive movement, or hypertonicity, involves qualitative and 
subjective scales such as the Modified Ashworth Scale (MAS) for spasticity or the Unified 
Parkinson’s Disease Rating Scale (UPDRS) for rigidity. Inaccurate and inconsistent assessments 
may occur depending on the rater’s level of experience and scale interpretation. Recently, 
researchers have been developing medical training simulators that mimic hypertonicity to aid the 
training of these clinician learners. However, there is a lack of quantitative data representing the 
kinetic and kinematic characteristics of these abnormal muscle behaviors. Thus, we developed a 
portable measurement device (the PVRM – Position, Velocity, and Resistance Meter) that 
measures the joint angle, velocity, and muscle resistance of the upper-arm extensor and flexor 
muscles. In Study 1, the accuracy and reliability of the PVRM was validated by comparing its 
measurements to a commercial dynamometer (Biodex), a gold standard for measuring 
biomechanical data. The PVRM measurements were similar to the gold standard Biodex 
measurements during the passive flexion movement, since the residuals for all measurements were 
between 1-13%. Therefore, the PVRM was able to quantify behavioral features of spasticity (e.g., 
catch-release behavior), rigidity (e.g., uniformly elevated muscle tone), and healthy (e.g., no 
muscle resistance) subjects. In Study 2, we conducted a clinical study of 38 participants using the 
validated PVRM to establish a database quantifying different levels of spasticity (n=15, MAS 1-
4); rigidity (n=11, UPDRS 1-3), and normal healthy (n=12) behavior of the biceps and triceps 
during passive flexion and extension of the elbow. Spasticity subjects demonstrated stretch speed 
and MAS score dependent hypertonia marked by a catch-release behavior, resulting in a convex 
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parabolic stretch speed profile. Rigidity subjects exhibited uniformly increased muscle tone that 
was dependent on UPDRS score but independent of stretch speed. The PVRM can provide a 
database for development of physical training simulators to realistically mimic hypertonicity and 
serve as a clinical measurement tool to reliably quantify the type and degree of hypertonicity.  
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CHAPTER 1: INTRODUCTION 
1.1 OVERVIEW OF SPASTICITY AND RIGIDITY  
1.1.1 SPASTICITY  
The physiological definition of spasticity was introduced by Lance et al., who described 
spasticity as “a motor disorder characterized by a velocity dependent increase in tonic muscle 
reflexes (TSR) with exaggerated tendon jerks, resulting from hyperexcitability of the stretch 
reflex” [1]. A spastic muscle exhibits three main behavioral features during passive movement of 
the associated joint: 1) increased muscle resistance (i.e. hypertonia) due to a decreased threshold 
of tonic and phasic stretch reflexes [2], 2) catch-release behavior (or clasp-knife phenomenon), 
manifested by a velocity dependent increase in muscle resistance [3–5], and 3) limited range of 
motion, a byproduct of prolonged immobilization due to severe spasticity [1]. Therefore, these 
behavioral features are important signs for distinguishing spasticity from other abnormal muscle 
behaviors, namely rigidity.  
Hypertonia (i.e., abnormally high level of muscle tone or resistance due to spasticity or 
rigidity) is related to hyper-excitable reflex contractions that resist the passive stretch of the 
affected muscle [1,6,7]. For healthy individuals, the passive movements of the limbs do not 
activate TSR or cause reflex muscle contraction below a certain stretch speed threshold (e.g., 
200˚/s) [8,9]. However, a spastic muscle’s TSR is altered, causing reflex muscle contraction at 
low stretch speeds (35˚/s) [1,9]. As the stretch speed is increased, the muscle contraction is 
intensified [10,11]. In addition, these muscle contractions became less sensitive when muscle 
length is increased [10,12,13]. The degree of muscle tone may vary depending on the severity of 
spasticity, so understanding the relationship between the magnitude of hypertonia and the 
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severity of spasticity may be valuable for monitoring changes in spasticity. However, 
quantification of hypertonia is not well documented. Thus, investigation of hypertonia from 
different levels of spasticity is needed.  
The presence of catch-release behavior is another pathophysiological result of the 
overactive TSR initiated at fast stretch speed [1]. After the onset of muscle tone due to stretch 
reflex contractions, the stretch speed decreases below the reflex threshold, reducing the reflex 
contraction and hypertonia [1]. In clinical practice, catch-release behavior refers to an abrupt 
increase in muscle tone (i.e. catch) at a certain joint position (i.e., catch angle) followed by a 
sudden drop of muscle resistance (i.e. release) [1]. For the majority of severe spasticity patients, 
the catch angle was reported to happen earlier in the range of motion [14–19]. Therefore, catch-
release behavior can be a useful feature to not only distinguish spasticity from other types of 
muscle conditions but also classify different levels of spasticity. 
Limited range of motion is another behavioral feature of spasticity. While muscle tone 
may arise due to a neural component such as the hyperexcitability of the TSR, non-neural 
components may cause hypertonia due to the loss of compliance of soft tissues (i.e. tendons, 
ligaments, joints) [1]. Thus, the presence of neural and non-neural components of resistance 
interfere with a patient’s daily movements and activities, causing reduced range of motion and 
continuous flexion of the affected muscle group for a long time [1]. In addition, certain muscles 
(e.g., the lower and upper limb flexors) become immobilized in a shortened length due to paresis 
[25]. This immobilization in a shortened position, seen mainly for severe spasticity patients, is 
the main reason for developing soft tissue contracture and limited ROM [20–22]. Hence, looking 
for reduced range of motion can be important to classify severe from mild spasticity patients.  
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1.1.2 RIGIDITY  
Rigidity, characterized by increased stiffness of muscles, is one of the cardinal motor 
symptoms of Parkinson’s disease (PD) along with resting tremor and bradykinesia [23], [24]. 
Although rigidity may appear in different forms such as cogwheel rigidity (rigidity superimposed 
by tremor) or lead pipe rigidity (uniform throughout the whole range of motion) stemming from 
various neurological disorders, we focused on investigating lead pipe rigidity originating from 
PD (parkinsonian rigidity) in our study due to subject availability. While rigidity may occur 
during a voluntary movement (i.e. active rigidity), lead pipe rigidity shows symptoms of 
increased muscle resistance during rest (static component of TSR) and passive stretch (dynamic 
component of TSR) [24–26]. The degree of muscle resistance in one limb may be further 
increased through activation, a clinically well-known phenomenon of reinforcing rigidity in one 
limb by requesting voluntary movements of the contralateral limb [27]. Thus, the main 
behavioral feature of lead pipe rigidity is uniformly increased resistance that can be enhanced 
through activation during passive movement. 
The underlying pathophysiological mechanism behind rigidity is still unclear [28–31]. 
Some researchers reported that rigidity, unlike spasticity, does not originate from 
hyperexcitability of stretch reflexes [30], [34]. The tendon jerks and H-reflexes are almost 
normal in patients with parkinsonian rigidity [28,30,32–34]. Instead, these researchers found 
intrinsic changes in muscle properties that caused abnormally high elasticity (stiffness), 
contributing to hypertonia regardless of stretch speed [35]. However, others claimed that rigidity 
was affected by velocity-dependent stretch reflexes, causing difficulty in discriminating the 
physiological mechanisms underlying spasticity and rigidity [28,30,36]. Yet, one common 
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finding of rigidity is the biomechanical measurement of increased muscle tone across the range 
of motion [29–31,37,38].  
 It is still unclear if the increased resistance of rigidity is proportional or even related to 
stretch speed. Some studies report rigidity is independent of stretch velocity [31,39], while other 
studies reported there is a dependence in stretch velocity [30,40,41]. Justifying the existence of 
stretch speed dependency was difficult, since some studies relied purely on subjective clinical 
evaluation of rigidity while other studies had only a limited number of test subjects [30,31,39–
41]. Colin et al. claimed that the stretch speed dependency of stretch reflex and the minimum 
stretch speed to produce stretch reflex of rigidity change with respect to the progression of PD 
[26]. For example, the stretch reflex is related to the stretch velocity in the early stages of PD but 
becomes less so as the disorder progresses [26]. Also, they reported that the velocity dependence 
of the stretch reflex is more apparent in extensors than flexor muscle groups [26]. With more 
progression of PD and severe rigidity, the stretch reflex becomes more evident beginning in 
flexors and later in extensors, most commonly in the most stretched position of biceps, triceps, 
and quadriceps [26]. Also, patients with more severe rigidity showed a production of stretch 
reflex electromyographic (EMG) response at low stretch speeds, while patients with mild rigidity 
were characterized by a high stretch speed for production of stretch reflex EMG response [26]. 
However, these claims were based on descriptive statistics on limited parameters such as elbow 
angle and EMG data of rigid muscles. Thus, more in-depth studies involving computation of 
parameters related to kinetic and kinematic data need to be conducted to verify the stretch speed 
dependency of muscle resistance for rigid arms.  
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1.2 CLINICAL ASSESSMENT OF SPASTICITY AND RIGIDITY  
1.2.1 MODIFIED ASHWORTH SCALE (MAS), MODIFIED TARDIEU SCALE (MTS), 
AND UNIFIED PARKINSON’S DISEASE RATING SCALE (UPDRS)  
 
Hypertonicity is clinically assessed using qualitative scales (e.g., the Modified Ashworth 
Scale (MAS) and Modified Tardieu Scale (MTS) for spasticity and motor section 3 (rigidity) of 
the Unified Parkinson’s Disease Rating Scale (UPDRS)) (Tables 1.1-1.3) [42–44]. During the 
muscle tone assessment, the clinician examines for the presence of spasticity, rigidity or other 
abnormalities of tone. To assess for spasticity, the patient is instructed to relax the affected 
muscle and let the clinician passively stretch (i.e., manually lengthen the muscle when it is not 
activated) the muscle at multiple speeds. Like the spasticity examination, rigidity is judged on 
slow passive movement of major joints with the patients in a relaxed position while the examiner 
manipulates the limbs. However, unlike spasticity, rigidity examination involves two passive 
stretch tests: a first test without an activation maneuver and, if no rigidity is detected, a second 
test with activation maneuver (i.e. tapping fingers, fist opening/closing, or foot tapping in the 
contralateral limb not being tested) [44]. Depending on the level of resistance, the clinician 
assigns a score that is proportional to the severity of spasticity or rigidity. MAS and MTS are six-
point scales starting with a score of 0 (no spasticity) to a score of 5 (severe spasticity), while 
UPDRS is a five-point scale starting with a score of 0 (no rigidity) to a score of 4 (severe 
rigidity). Although the MTS is regarded as a more appropriate assessment by some researchers 
since it considers the stretch speed dependence of muscle tone at various speeds, the MAS is 
more commonly used due to its simple and straightforward protocol [45–50]. Thus, the 
remaining thesis will discuss using the MAS for spasticity and UPDRS for rigidity.  
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Table 1.1. Modified Ashworth Scale (MAS) for assessing spasticity [42] 
Score Description 
0 (0)a No increase in muscle tone 
1 (1) 
Slight increase in muscle tone, manifested by a catch and release or by minimal 
resistance at the end of the range of motion when the affected part(s) is moved in 
flexion or extension 
1+ (2) Slight increase in muscle tone, manifested by a catch, followed by minimal 
resistance throughout the reminder (less than half) of the range of motion 
2 (3) More marked increase in muscle tone through most of the range of motion, but 
affected part is easily moved 
3 (4) 
Considerable increase in muscle tone, passive movement difficult 
4 (5) 
Affected part is rigid in flexion or extension 
a Numbers in parenthesis are variants of the Modified Ashworth Scale [51]. This scoring 
convention is used in this thesis. 
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Table 1.2. Modified Tardieu Scale (MTS) for assessing spasticity [43].  
Score Description 
0 No resistance throughout passive movement 
1 Slight resistance throughout, with no clear catch at a precise angle 
2 Clear catch at a precise angle followed by release 
3 Fatigable clonus (<10 secs) occurring at a precise angle 
4 Un-fatigable clonus (>10 secs) occurring at a precise angle 
5 Joint immobile 
 
Table 1.3. Section 3 (Rigidity) of the Unified Parkinson’s Disease Rating Scale (UPDRS) [44].  
Score Description 
0 No rigidity 
1 Slight or detectable rigidity only detected with activation maneuver  
2 Mild to moderate rigidity detected without the activation maneuver, but full range 
of motion is easily achieved. 
3 
Marked rigidity detected without the activation maneuver; full range of motion is 
achieved 
with effort. 
4 Severe rigidity detected without the activation maneuver and full range of motion 
not achieved. 
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1.2.2 PROBLEMS OF CURRENT CLINICAL ASSESSMENT METHODS  
The main problem of current clinical examination methods of spasticity and rigidity is the 
heavy dependence of the assessor’s previous training and clinical experience due to the 
qualitative descriptions of the scales that are open to interpretation (Tables 1.1-1.3) [52–55]. 
Thus, it is difficult for clinician learners to acquire the skill for reliable and accurate assessment 
of spasticity or rigidity. Hands-on evaluation experience is required before being able to 
clinically assess spasticity and rigidity, so current training methods depend on inviting practice 
patients or asking other students to mimic hypertonicity for each other. This results in 
inconsistent and inefficient training due to limited availability of practice patients [55]. 
Therefore, the development of training simulators that can consistently mimic realistic 
hypertonicity at different levels has recently been explored to aid the current training practices 
[56–61].  
 
 
1.3 TRAINING SIMULATORS AND MEASUREMENT DEVICES  
1.3.1 TRAINING SIMULATORS   
There have been primarily two types of training simulators for replicating hypertonicity: 
electromechanical training simulators [56–58] and mechanical training simulators [59–61] 
(Figure 1.1) For the electromechanical designs, brushed or brushless DC motors simulated 
muscle resistance, and a braking system (e.g., a servo disc brake or magneto-rheological fluid 
viscous brake) replicated the stretch speed dependency and catch-release phenomenon for 
spasticity simulation. The advantage of the electromechanical designs was the flexibility of 
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programming various torque profiles to realistically generate different levels and types of 
hypertonicity. Various behavioral features (e.g., catch-release behavior, increased muscle tone, 
and reduced ROM) were easily implemented following a mathematical model built from 
quantitative data collected from real spasticity/rigidity patients. However, disadvantages of such 
designs were the use of potentially expensive electrical components and requirement of a power 
supply, limiting cost efficiency and portability [59]. So, a fully mechanical passive training 
simulator that utilized viscous hydraulic damper and a mechanical linkage system was developed 
to provide a stretch speed and position dependent haptic feedback [59–61]. Muscle resistance 
was created by forcing a viscous fluid to flow through size-adjustable orifices on the damper’s 
piston head, allowing replication of different levels of spasticity and stretch speed dependent 
tone behavior. Regardless of the type of simulators, there is a definitive need in the research 
community for a comprehensive database that quantifies the behavioral features of abnormal 
muscle conditions in order to fine tune the simulators to realistically mimic all levels of 
hypertonicity [17,19,55–62]. Thus, measurement devices were developed to establish a database 
quantifying the passive stretch responses of spasticity and rigidity. Research related to 
developments of exoskeleton, orthosis, and other assistive/rehabilitation devices could also 
benefit from this database for proper component selection [63–67]. For example, when 
developing a soft exo-glove, knowing the magnitude of muscle resistance of spastic fingers can 
be useful for selecting a properly sized motor that is powerful enough to maneuver the spastic 
fingers for grabbing differently shaped objects while preventing excessive torque applied on the 
joints [63,66].  
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Figure 1.1. (a) Electromechanical training simulator using DC motor and MR fluid system [56] 
and (b) mechanical training simulators using hydraulic damper and linkage system [59]. 
 
1.3.2 MEASUREMENT DEVICES  
Different types of measurement devices were developed by researchers to quantify the 
upper-arm muscle behavior of spasticity and/or rigidity (Figure 1.2) [14,28–30,47]. These 
devices collected data on one or more of the following measurements: kinetic data relating to 
increased muscle tone (applied torque, stiffness, and/or energy), kinematic data (angular position 
and/or angular speed), and electromyographic (EMG) signal data [14,28–30,47]. To collect 
kinetic data, sensors (e.g., rotational torque sensor, force transducers connected to air pads, or 
load cells) were used [14,29,30,68]. To collect kinematic data, sensors, namely gyroscopes, 
potentiometers, and flexible electro-goniometers, were utilized [14,29,30,68]. Finally, non-
invasive surface EMG (sEMG) electrodes were used for measuring EMG activity [28]. To 
manipulate the subject’s arm, either an electromechanical actuator (e.g., DC motor) or a clinician 
stretched the arm. In terms of study design, some studies investigated both spasticity and rigidity 
population [28,30], while other studies only performed tests on spasticity or rigidity exclusively 
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[14,29]. The specific hardware design, study design, post processing of data, and limitations of 
these studies are explained in the next few paragraphs. 
 
Figure 1.2. (a) Measurement device developed by Lee et al. [30] (b) measurement device developed by 
Prochazka et al. [29] 
Lee et al. developed a motor driven muscle tone measurement system in order to 
characterize the velocity related properties of hemiparetic spasticity (n=12), parkinsonian rigidity 
(n=16), and normal (n=12) muscle tone of upper-arm flexor muscle groups [30]. The system 
included a motor with angular position sensor, torque sensor, and surface EMG electrodes for 
monitoring muscle activity of biceps. The forearm of the test subject was strapped to the 
apparatus and stretched at four different speeds (40, 80, 120, and 160 ˚/s). For spasticity and 
rigidity subjects, the more affected forearm was tested. For controls, the dominant arm side was 
tested. Three reactive torque parameters (average speed dependent reflex torque (ASRT), 
velocity sensitivity of ASRT (VASRT), and segmented ASRT (SART)) were proposed by the 
authors and used to describe the velocity-dependent muscle tone behavior (Figure 1.3). To model 
the measured torque (𝑇), a linear model that consisted of inertial (𝐼), viscous (𝐵), elastic stiffness 
(𝐾) components, and constant offset (𝐶) was proposed described in Equation 1 [69].  
(a) (b) 
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𝑇 =  𝐼?̈? + 𝐵?̇? + 𝐾𝜃 + 𝐶                                                               (1) 
To observe only the components relevant to muscle resistance (𝐵 – velocity dependent viscous 
component, 𝐾 – elastic component in Equation 1), the inertial (𝐼?̈?) and gravitational effects from 
the stretched limb and the manipulator (𝐶) were removed. At very slow velocity, the muscle 
resistance induced by the velocity factor is trivial, but the gravitational effect remained the same 
as for higher stretch velocities. Essentially, the baseline torque (torque measured at a very slow 
stretch speed of 5°/s, dashed line in Figure 1.3 (a)) represents the elastic and gravitational parts 
of the measured torque during stretch. Hence, after subtracting the baseline torque from the high 
velocity torque, the shaded area during the constant phase can be extracted as the velocity 
dependent component of reactive torque (Figure 1.3(a)). The normalized area (that is, the 
averaged amplitude of the shaded area)—defined as averaged speed dependent reflex torque 
(ASRT)—was used for quantifying the velocity dependent component of increased muscle tone. 
To analyze the velocity dependent properties of ASRT, the VASRT was compared among the 
three groups (Figure 1.3(b)). The slope of the regression line represents the averaged VASRT for 
each group (Figure 1.3(b)). To represent the position related patterns of increased muscle tone, 
SASRT was derived from the reactive torque as shown in Figure 1.3(c). 
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Figure 1.3. Examples of ASRT (a), VASRT (b), and SASRT (c). ASRT is the normalized area of the 
shaded region. VASRT is the slope of the ASRT at different stretch speeds. SASRT is the segmented torque 
data between P1 (start of constant stretch speed region and acceleration near zero) and P2 (end of constant 
stretch speed region). [30] 
 
 The results suggested that the apparatus and these metrics were able to differentiate the 
three subject groups at different stretch speeds. However, there were several limitations to this 
study. First, the measurement apparatus was bulky and may have involved long setup time due to 
its large mechanical structure, limiting its usability and practical use in a clinical setting. The test 
setup required the subject to be supine, which may impose difficulty for severe spasticity and 
rigidity patients with limited mobility and contractures [22,70–73]. Second, the study only 
investigated inter-group differences, but no investigation was made on intra-group differences 
(i.e., severity of hypertonicity within each group). Ambiguities between different MAS levels 
(a) 
(b) 
(c) 
5˚/s 
40˚/s 
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were discovered due to unclear description of these scales [17,19,74,75]. Thus, quantifying the 
differences between various levels of severity of hypertonicity is needed to overcome the 
limitations of these qualitative scales. Third, the relatively complex definitions of ASRT, 
VASRT, and SASRT may be difficult for clinicians to understand. In clinical evaluation of 
spasticity, simple metrics such as range of motion, presence of catch, catch angle, are usually 
documented. This measurement device and its protocol do not provide the clinician with the 
metrics that they use commonly during evaluation. Fourth, the study scope was limited since it 
only focused on upper-arm flexor muscles; spasticity and rigidity are also found in extensor 
muscles as well. 
Pandyan et al. developed a non-invasive biomechanical measuring device, which could 
be used in clinical practice, to quantify spasticity at the elbow joint [14]. The device utilized a 
force transducer and an electro-goniometer to measure applied force and passive range of 
movement, respectively. The resistance to passive movement (defined by them as RPTM), 
presence of catch, and average stretch speed were computed for 16 subjects with various levels 
of spasticity. While the device was made to be clinician-friendly and portable, limitations were 
found in terms of the hardware, testing protocol, test subjects, and data processing. First, there 
were no surface EMG sensors used to monitor the status of muscle activity. Thus, it was difficult 
to assess the subject’s compliance associated with the inability to relax their muscles. Second, 
the point of application of force was not standardized, allowing inaccurate readings of muscle 
resistance. It is critical to standardize the testing protocol and assessment techniques, especially 
make the direction, magnitude, and location of the applied force consistent [29,75,76]. A simple 
free body diagram of a passively moving limb with hypertonia reveals that the measured torque 
is linearly proportional to the distance from the applied force location and rotating axis (i.e., 
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elbow joint). An example of a possible scenario is the ambiguity arising from the similar torque 
measurements between a mildly spastic arm with the force applied close to the elbow joint and a 
severely spastic arm with the force applied away from the elbow joint. Third, only spasticity 
subjects from MAS 0 to 2 were recruited in this study, excluding more severe spasticity subjects 
(MAS 3-4) and rigidity subjects. Thus, comparison between different muscle conditions was not 
possible. Finally, their definition of the RTPM was inaccurate. Their computation of the muscle 
resistance did represent spasticity accurately due to the inclusion of inertial effect that varied 
depending on the subject’s arm weight and geometry. Any experimental protocol that involves 
torque measurement of a moving body should remove the inertial effect when analyzing different 
components of torque (i.e. muscle resistance) since the product of inertia and acceleration 
inherently exists. Therefore, the combined torque of inertial effect and muscle resistance is 
measured by the torque sensor. For example, if one were to measure the muscle resistance of a 
human forearm during passive movement, any acceleration or deceleration about an axis will 
naturally induce an inertial term. This inertial term along with muscle resistance will always be 
coupled regardless of the rotational axis, so it is important to remove the inertial term to analyze 
the muscle resistance alone.  
 Prochazka et al. developed a quantification device, consisting of a gyroscope for 
monitoring stretch speed and a force transducer that read the applied force on the limb, to 
quantify parkinsonian rigidity at the elbow [29].  Four subjects with idiopathic Parkinson’s 
disease and five normal controls were recruited. The examiner evaluated the UPDRS score of the 
wrist and elbow with and without activation maneuvers. Mechanical impedance, the vectorial 
sum of elastic stiffness and viscosity, were computed to quantify different levels of UPDRS 
scores. The study was able to correlate the UPDRS score to the computed mechanical 
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impedance, validating the UPDRS scale. However, one limitation was the restricted scope of 
study since spasticity subjects were excluded. While the calculation of mechanical impedance 
can distinguish different levels of rigidity, such quantification may not work for differentiating 
spasticity from rigidity, since spasticity also involves high degree of elastic stiffness and 
viscosity (i.e., high mechanical impedance) similar to rigidity. Another limitation was the lack of 
specification of stretch speed. The clinicians involved in the study were not given specific 
instructions on the stretch speed. It is important to specify and report the stretch speeds because, 
while rigidity muscle tone has been reported to be less speed dependent than spasticity, 
numerous reports indicated that rigidity showed observable stretch speed dependency, especially 
with extensor muscles [40], [41], [30].  
Mullick et al. quantified spasticity and rigidity existent in upper-arm flexor and extensor 
muscle groups using a manipulandum. The study recorded joint angle and velocity and an 
electromyography (sEMG) signal for spasticity (n=10), rigidity (n=11), and control (n=6) 
subjects from slow (8˚/s) to fast stretch speeds (160˚/s) [28]. This study primarily focused on 
computation of three parameters related to tonic and dynamic stretch reflex thresholds (ST): 1) 
tonic ST, the angle when the muscles are activated during quasi-static stretching (low velocity 
close to zero); 2) dynamic ST, the angle when the muscles are activated during non-zero velocity 
of muscle stretching; and 3) sensitivity of dynamic ST, which represents the sensitivity of the 
stretch reflex activity to different stretch speeds. The study proposed that these metrics could 
discriminate spasticity from rigidity. However, the tedious setup of sEMG system (e.g., 
preparation of the skin, and the large size of the manipulandum due to the presence of a motor) 
can limit its practicality in a clinical environment where reliable evaluation needs to be done in 
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short time [14]. Also, the differentiating the severity of hypertonicity was not possible using this 
apparatus and metrics, as the author reported.  
 
1.3.3 QUANTIFICATION OF CATCH-RELEASE BEHAVIOR  
To investigate the catch-release behavior of spasticity, a quantitative definition of such 
behavior had to be defined among researchers [14,47,77]. Different definitions of catch have 
been introduced by other studies, but most definitions were not comprehensive or accurate 
enough due to limited number of sensors used in the studies. For example, one study defined 
catch as an instance during a passive movement when the clinician’s stretch speed decreased 
below 50˚/s due to increased muscle tone [77]. Relying solely on stretch speed is not robust or 
accurate enough to detect a catch, since other factors can affect the stretch speed: the clinician’s 
preference on stretch speeds or different arm weight. In addition, predefining the speed threshold 
as 50˚/s was arbitrary and hard to justify, since only four subjects with spasticity were tested.  
Another study’s definition of catch was the instance when the changing rate of resistive torque 
(i.e., stiffness) was maximum [47]. This definition was too general to characterize catch 
behavior, since rapid increase in stiffness can be seen in both spasticity and rigidity subjects. 
Other studies detected catch behavior by relying on the clinician’s subjective perception that 
corresponded to a transient increase of resistance [14]. Thus, a robust quantitative definition of a 
catch needs to be established that incorporates both kinetic and kinematic data.  
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1.4 PVRM – POSITION, VELOCITY, AND RESISTANCE METER   
 To overcome the limitations of the previously mentioned measurement devices, a 
portable measurement device (the PVRM - Position, Velocity, and Resistance Meter) was 
developed for objectively quantifying spasticity and rigidity. The PVRM consisted of two 
modules (moving and main) and three surface electromyographic (sEMG) electrodes (biceps, 
triceps, and reference). The moving module, containing an IMU and load cell, was placed on the 
moving body segment (i.e. lower arm), while the main module, which contained another IMU 
and processed, transmitted, and computed the sensor data, was attached on the adjacent 
stationary body segment (i.e. upper arm). The goal of the PVRM was to provide a compact and 
portable device that can accurately and reliably measure the kinetic and kinematic data of 
spasticity and rigidity in a clinical setting. One design feature of the PVRM was its small size 
and portability for practical clinical use. The use of small inertial measurement unit sensors and a 
miniature uniaxial load cell minimized the overall physical size of the PVRM. While motors 
were used in previously mentioned studies, the drawbacks of motors for stretching the patient’s 
arm (e.g., bulky nature, cost, maintenance, and setup time) motivated the design of the PVRM to 
exclude these powertrain devices. Rather, we focused on developing a wearable device that 
allows a clinician to stretch the patient’s limb via his or her hands. This reduced the risks of 
injury and made the patient feel comfortable during assessments by allowing a haptic feedback 
for the clinician. In addition, a Bluetooth module transmitted the PVRM data wirelessly in order 
to improve the user-experience and reduce the setup time. Another design feature of the PVRM 
was its universal application that can be used in not just for the upper-extremity but also for the 
lower-extremity in both flexion and extension. Spasticity and rigidity can occur in both the upper 
and lower-extremities, so it is important for the quantification device to be able to accommodate 
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various muscle geometry. Thus, Velcro straps with adjustable lengths increased the PVRM’s 
adjustability. Also, sEMG electrodes monitored for the passivity of relevant muscles, since the 
clinical assessment of hypertonicity requires muscles to be fully relaxed. Hence, the PVRM 
development can be helpful for the researchers and neurologists in the field of spasticity and 
rigidity by providing useful data explaining spastic and rigid muscle behavior in different muscle 
groups.  
The PVRM data processing involved key outcome parameters that can distinguish not 
only different types of muscle disorder but also the severity of muscle disorder. Some of these 
parameters (e.g., catch angle and range of motion) were relatable to clinicians. Other parameters 
(e.g. stretch speed dependency of hypertonia) were defined to differentiate spasticity from 
rigidity. Proper filtering of data and removal of gravitational and inertial effect were performed 
to analyze just the spasticity and rigidity relevant data. Finally, we provided a strict testing 
protocol for reliable comparison between subjects. The quantification of resistance was 
computed as applied torque instead of applied force for more accurate representation of 
resistance. The PVRM moving module was placed at a similar location for all subjects, and the 
distance between the applied force and the elbow joint was always recorded. Also, the average 
stretch speed of each assessment was computed to repeat the assessment if the stretch speed was 
too slow or too fast. In addition, we introduced a more robust quantitative definition of catch-
release behavior that involved both kinetic and kinematic data. Therefore, the PVRM data 
processing aimed to provide accurate database of spasticity and rigidity patient population 
through rigorous control of testing procedure and computation of clinically relevant metrics.  
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1.5 THESIS ORGANIZATION  
This thesis presents the design, validation, and clinical studies of a portable measurement 
device (the PVRM – Position, Velocity, and Resistance Meter) that can accurately and reliably 
quantify muscle behaviors of various levels of spasticity and rigidity during passive stretch about 
the elbow joint. A validation study was necessary to ensure accurate measurement of muscle 
behavior. Then, a preliminary clinical study was performed to provide a database for optimizing 
medical training simulators and quantitatively understanding spasticity and rigidity.  
 Chapter 1 gives a brief introduction of current understandings and behavioral features of 
spasticity and rigidity. Also, commonly used clinical scales for assessing hypertonicity and the 
limitations of these scales were reviewed. Previous developments of medical training simulators 
and measurement devices that address the drawbacks of the current clinical scales were 
discussed. To aid the optimization of simulators and understand hypertonicity, the need for a 
newly developed measurement device (PVRM) that overcomes the limitations of the previous 
measurement devices was established. 
Chapter 2 presents the design and validation of the PVRM used for measuring elbow joint 
angle and stretch speed, and muscle resistance of the upper-arm extensor and flexor muscles. The 
PVRM accuracy was validated by comparing the measurements from the PVRM to a gold standard 
dynamometer (i.e. Biodex System 3). The PVRM data and Biodex data were collected as the 
Biodex performed a series of passive elbow flexion and extension cycles on test subjects wearing 
the PVRM. Results indicated that the PVRM can be used to accurately quantify behavioral features 
of spasticity and rigidity: the catch-release behavior and increased muscle tone during passive 
stretches.  
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 Chapter 3 presents the results of a preliminary clinical study performed on various levels 
of spasticity and rigidity subjects using the validated the PVRM to provide a database quantifying 
hypertonicity. Key outcome parameters were defined and analyzed to quantify the behavioral 
features of spasticity and rigidity in association to the type and severity of the muscle disorder. A 
discussion relating the quantifications and the pathophysiology of spasticity and rigidity were 
made.  
 Chapter 4 discusses the necessary design improvements of the PVRM for clinical use and 
gives suggestions of future study designs.  
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CHAPTER 2: DESIGN AND VALIDATION STUDY OF THE PVRM (POSITION, 
VELOCITY, AND RESISTANCE METER) 
 
2.1 ABSTRACT 
 The study goal was to design and validate a wearable and portable measurement device 
(the PVRM – Position, Velocity, and Resistance Meter) that quantifies unique kinetic and 
kinematic behavior of hypertonicity (i.e., spasticity and rigidity) during passive joint movement. 
In this study, the PVRM was used to measure joint angular position, velocity, and muscle 
resistance during passive flexion of the elbow. The PVRM accuracy was validated by comparing 
the measurements from the PVRM to a gold standard dynamometer (Biodex System 3). The data 
from the PVRM and Biodex were collected as the Biodex performed a series of passive elbow 
flexion cycles on test subjects wearing the PVRM. Five subjects with hypertonicity (n=3 for 
spasticity, n=2 for rigidity) and five healthy controls were tested. The absolute residual error 
between the PVRM and the Biodex for joint position, velocity, and resistance were less than 3˚, 
5˚/s, and 0.2 Nm, respectively. The PVRM provides a compact, easy to use measurement device 
to quantify upper-arm hypertonicity. The PVRM can not only help researchers gain additional 
insight into the quantification of spasticity and rigidity, but also allows clinicians to make more 
reliable quantitative assessments of their patients. 
 
2.2 INTRODUCTION 
 Spasticity and rigidity are two common categories of muscle hypertonicity. Spasticity 
involves a stretch velocity-dependent increase in tone, involuntary muscle spasms, and a catch-
release behavior (a rapid increase and decrease in muscle tone) [1,78]. This behavior results from 
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an upper motor neuron lesion and is usually seen in neurological disorders such as stroke, spinal 
cord injuries, multiple sclerosis, and cerebral palsy [1]. Rigidity involves a stretch velocity-
independent increase in tone throughout the entire range of motion and loss of motor control and 
is typically observed with Parkinson’s disease [79].  
 Clinically, accurate assessment of spasticity or rigidity is necessary for effective 
management and treatment [80–83]. Current clinical assessment of spasticity and rigidity involves 
categorizing a patient’s severity level based on a five- or six-point integer qualitative scale, such 
as the Modified Ashworth Scale (MAS) [42] or the Modified Tardieu Scale (MTS) [84]  for 
spasticity, and the motor section of the Unified Parkinson’s Disease Rating Scale (UPDRS) for 
rigidity [44]. The assessments involve a clinician performing passive stretches of the patient’s 
affected muscles while the clinician observes and feels for the degree of increase in tone (ranging 
from “slight”, “marked”, and “considerable increase” in tone [42]) or presence of catch-release 
behavior [42,44,84]. For newly trained clinicians, consistent and reliable assessments of spasticity 
and rigidity may be difficult since these evaluation methods heavily rely on the rater’s personal 
experience and interpretation of the scale. The use of these qualitative scales usually results in poor 
consistency and low reliability (some reporting as low as 56% [53]) [52,75,85–89]. In addition, 
training opportunities for new clinicians are limited due to lack of practice patients and practical 
tools to experience different levels of spasticity and rigidity [53].  
 A few research groups have developed devices to assess hypertonicity quantitatively 
[30,43,90–96]. However, there are limitations to these devices: difficulty of practical clinical use 
due to long setup time and bulky size [97], lack of standardized testing protocol which led to 
inaccurate measurement [14,29], limited study scope that investigated exclusively only spasticity 
or rigidity [14,29], or sole reliance on electromyographic (EMG) measures that have a long setup-
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time and strict test protocols [28].  
 To address the limitations of these devices, we present the design and validation testing of 
a measurement device (the PVRM – Position, Velocity, and Resistance Meter) to quantify 
spasticity and rigidity. The PVRM consisted of small modules that can be attached to a patient’s 
body segments to measure kinematic and kinetic data, such as angular position and velocity, and 
the force applied by the clinician to passively stretch the joint. This applied force is interpreted as 
muscle tone resistance felt by the clinician. The PVRM design goals were to make a compact, 
light-weight, and portable measurement device that can be attached quickly and with minimum 
setup requirements. A validation study was conducted to assess the accuracy of the PVRM. The 
measurements of PVRM accuracy were validated by comparing the values from the PVRM to a 
gold standard dynamometer (Biodex, System 3, Shirley, New York, USA). The data from the 
PVRM and Biodex were collected as the Biodex performed a series of passive elbow flexion cycles 
on a test subject wearing the PVRM modules. 
 
2.3 METHOD 
2.3.1 DESIGN 
 The PVRM was composed of two modules attached to the patient (main and moving), 
which were wired to a data processing module. To ensure that the muscles were passive during the 
stretch test, muscle activation status was checked using a commercially-available surface EMG 
measurement system (Bagnoli, Delsys, Natick, Massachusetts, USA). The data processing module 
and the Delsys EMG system were connected via USB cables to a computer, where the PVRM and 
EMG data were processed to calculate the angular position and velocity, and muscle resistance as 
well as muscle activity (Figure 2.1). 
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 The device used two small commercial inertial measurement unit (IMU) sensors each 
containing a 3-axis accelerometer and a 3-axis gyroscope (MPU-6050, InvenSense, California, 
USA), a miniature uniaxial load cell (LCM 300; Futek, California, USA), and a micro controller 
(Uno; Arduino LLC; Italy). Each IMU measured acceleration and angular velocity about three 
orthogonal axes (x, y, z) of each module and output a 3D vector parallel to the x, y, z axes in a 
quaternion form by using an onboard Digital Motion Processing (DMP) algorithm [98].The 
moving module contained one IMU sensor and the load cell (Figure 2.2). The moving module was 
attached to the ulnar side of the wrist when assessing elbow flexion and radial side for extension. 
A load cell cover plate was used to connect the moving module to the Biodex lever arm so that the 
load was applied only on the cover plate. The main module contained the other IMU and was 
attached to the midpoint of the upper arm with the module facing laterally (Figure 2.1, 2.2). The 
positive z-axis of the main module pointed away and normal to the humerus. The data processing 
module contained the microcontroller, load cell amplifier shield (RB-Onl-38; RobotShop; 
Vermont, USA), and 𝐼2𝐶 multiplexer (TCA9548A; Texas Instruments, Texas, USA). The 
enclosures for these three modules were packaged in polylactic acid 3D printed enclosures. The 
main and moving modules were designed with built-in slots to accommodate a nylon strap with 
Velcro to secure the modules to the patient’s body segments. 
 The data processing module sampled the raw IMU and load cell data from the main and 
moving modules at 100 Hz. For each sampling of the raw data, a 13-component string of data was 
generated that included: sample number, running time, load cell reading, and IMU data (angular 
velocity and quaternion vector from each IMU). The Delsys EMG system sampled the EMG 
signals of biceps and triceps at 1000 Hz.  
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Figure 2.1. The PVRM and Delsys EMG general setup. 
 
Figure 2.2. The PVRM modules: (a) the main module contained IMU 1, (b) the moving module contained 
IMU 2 and load cell. 
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2.3.2 DATA PROCESSING 
 The joint angular position (𝜃) and velocity (𝜔) were computed using the readings of the 
IMUs of the main module (IMU 1) and moving module (IMU 2). Each IMU outputted four values 
(𝑎, 𝑏, 𝑐, 𝑑, where 𝑎 defines the amount of rotation and 𝑏, 𝑐, 𝑑 defines the axis of rotation in the 3D 
Cartesian space) representing a unit quaternion vector to quantify any rotation in 3D space (?⃑? ) 
relative to the initial coordinate frame of the IMU (?̂?, 𝒋̂, ?̂?) (Equation 1).  
𝒒𝒊⃑⃑  ⃑ = 𝑎 + 𝑏?̂?𝐢 + 𝑐?̂?𝐢 + 𝑑?̂?𝐢 , where 𝑖 = 1, 2          (1) 
 Quaternion representation was chosen over Euler angles due to quaternion’s simple 
composition and absence of gimbal lock problems [99]. The rotation matrixes of IMU 1 and 2 (𝑹1 
and 𝑹2 ) were derived from the quaternion values of the IMU 1 (𝒒𝟏⃑⃑ ⃑⃑ ) and the IMU 2 (𝒒𝟐⃑⃑ ⃑⃑ ), 
respectively, using Equation (2) [100]. Each column of the rotation matrix contained orientations 
of the local x, y, and z-axes of the rotated IMU relative to its initial coordinate frame (i = 1,2).    
 
𝑹𝒊 = [?⃑?   ?⃑?   𝒛 ⃑⃑ ] = [
𝑎2 + 𝑏2 − 𝑐2 − 𝑑2 2𝑏𝑐 − 2𝑎𝑑 2𝑏𝑑 + 2𝑎𝑐
2𝑏𝑐 + 2𝑎𝑑 𝑎2 − 𝑏2 + 𝑐2 − 𝑑2 2𝑐𝑑 − 2𝑎𝑏
2𝑏𝑑 − 2𝑎𝑐 2𝑐𝑑 + 2𝑎𝑏 𝑎2 − 𝑏2 − 𝑐2 + 𝑑2
].     (2) 
 Before any measurement data could be collected from the PVRM, a 5s calibration trial for 
the IMUs and load cell was required (Figure 2.3 (a)). The calibration was used to 1) zero the load 
cell readings, and 2) establish the initial coordinate frame for each IMU and also align the local 
coordinate frames of the IMUs relative to a fixed global coordinate frame, since the two IMUs’ 
coordinate frames were misaligned due to the absence of magnetometers. The fixed global 
coordinate frame was defined by using the orientation of the initial local coordinate frame of IMU 
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1 during the 5s calibration. The calibration procedure involved physically attaching the two 
modules together such that their coordinate frames were aligned parallel for 5s during which IMU 
and load cell data were collected (Figure 2.3 (a), light grey image). The load cell had no applied 
load. A calibration matrix (𝑹𝑐𝑎𝑙𝑖𝑏) was computed using Equation (3).  
𝑹𝑐𝑎𝑙𝑖𝑏 = 𝑹1𝑹2
−1.           (3) 
 During each calibration trial, the average of the 𝑹𝑐𝑎𝑙𝑖𝑏 (𝑹𝑎𝑣𝑔
𝑐𝑎𝑙𝑖𝑏) over the 5s of calibration 
data was computed for obtaining a more accurate calibration matrix. After the calibration, an 
updated rotation matrix of IMU 2 (𝑹𝟐
𝒖𝒑𝒅𝒂𝒕𝒆𝒅
) that was referenced from the global frame was 
computed using Equation (4).  
𝑹𝟐
𝒖𝒑𝒅𝒂𝒕𝒆𝒅
= 𝑹𝒂𝒗𝒈
𝒄𝒂𝒍𝒊𝒃𝑹𝟐.              (4) 
 To obtain 𝜃, the angular difference between the x-axes of IMUs 1 (𝒙𝟏⃑⃑⃑⃑ = first column of 𝑹𝟏) 
and 2 (𝒙𝟐⃑⃑⃑⃑ = first column of 𝑹𝟐
𝒖𝒑𝒅𝒂𝒕𝒆𝒅
) was computed using the dot product of the two vectors 
(Equation 5) (Figure 2.3(c)). 𝜔 was found by subtracting the gyroscopic readings about the z-axes 
of IMUs 1 from 2. The angular position and velocity data were filtered via an analog lowpass filter 
with a cutoff frequency of 50 Hz. 
𝜃 = cos−1(
𝒙𝟏⃑⃑ ⃑⃑  ∙𝒙𝟐⃑⃑ ⃑⃑  
|𝒙𝟏⃑⃑ ⃑⃑  ||𝒙𝟐⃑⃑ ⃑⃑  |
)                (5) 
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Figure 2.3. (a) The calibration procedure of the PVRM and (b, c) computation of elbow joint angular 
position (θ). 
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 Calculated muscle resistance (𝜏) had various contributions: the torque due to the applied 
force of the clinician (𝐹𝑎𝐿𝑎𝑟𝑚), inertial effect (𝐼𝑧𝛼), gravitational effect (𝐹𝑔𝑐𝑜𝑠(𝜃ℎ𝑜𝑟)𝐿𝑐𝑜𝑚), and 
unwanted moments (𝑀𝑢𝑤) due to tilting of the load cell (Figure 2.4). Equations (6, 7) show the 
sum of moment about z-axis (𝑀𝑧) and rearrangement of this equation for solving 𝜏, respectively. 
Here, 𝐹𝑎 and 𝐿𝑎𝑟𝑚 represents the applied force on the load cell and distance between elbow joint 
and load cell, respectively. 𝛼, 𝐹𝑔,𝜃ℎ𝑜𝑟 are the angular acceleration, force due to gravity, and angle 
with the global x-axis, respectively. The mass of moving body segment (forearm and hand) (𝑚), 
distance from the elbow joint to the center of mass (COM) of the moving body segment (𝐿𝑐𝑜𝑚), 
and rotational inertia of the moving body segment about the elbow joint or Z-axis (𝐼𝑧 ) were 
estimated using known anthropometric equations given the subject’s gender, body mass, and 
height [101]. A nine-point-moving-average filter was used to filter the calculated 𝜏 data after it 
was calculated.  
𝛴𝑀𝑧 = 𝐼𝑧𝛼 = 𝐹𝑎𝐿𝑎𝑟𝑚 − 𝐹𝑔 𝑐𝑜𝑠(𝜃ℎ𝑜𝑟) 𝐿𝑐𝑜𝑚 − 𝑀𝑢𝑤 − 𝜏.       (6) 
𝜏 = 𝐹𝑎𝐿𝑓𝑜𝑟𝑒𝑎𝑟𝑚 − 𝐹𝑔 𝑐𝑜𝑠(𝜃ℎ𝑜𝑟) 𝐿𝑐𝑜𝑚 − 𝐼𝑧𝛼 − 𝑀𝑢𝑤 .            (7) 
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Figure 2.4. Free-body diagram of a subject’s arm during passive movement. θ = 0˚ when the forearm was 
aligned to the upper-arm. 
 
2.3.3 SUBJECT DEMOGRAPHICS 
 Human subject testing was conducted to validate the accuracy of position, velocity, and 
resistance measurements of the PVRM during passive arm flexion. The measurements from the 
PVRM were compared to a gold-standard commercial robotic dynamometer (System 3, Biodex). 
A total of ten subjects were tested: three subjects with spasticity, two subjects with rigidity and 
five healthy control subjects (Table 2.1). The inclusion criteria for the spasticity and rigidity 
patients were: (a) 18-80 years of age, (b) stable neurological condition that causes spasticity or 
rigidity at the elbow joint, (c) no other significant neurological disorders in addition to the 
condition that causes spasticity or rigidity, (d) no history of musculoskeletal disorder at the elbow 
joint, and (e) could consent or be accompanied by someone with a power of attorney and ability 
to follow commands. The inclusion criteria for the control subjects were: (a) no history of abnormal 
hypertonic muscle behaviors or any neurological diseases that affect movement of the upper 
extremity, and (b) able to consent or be accompanied by someone with a power of attorney and 
32 
 
ability to follow commands. The exclusion criteria were: (a) history of paratonia, (b) recent injury 
to arm in the past 3 months, and (c) presence of tremor during passive stretch. The study was 
approved by the Institutional Review Boards at the University of Illinois College of Medicine at 
Peoria, the University of Illinois at Urbana-Champaign, and Bradley University. The human 
subject testing was conducted at Bradley University and informed consent form was obtained from 
all participants. 
 For participants with hypertonicity, a certified clinician (author ST) assessed and recorded 
the participant’s muscle behavior on the Modified Ashworth Scale (MAS) and Modified Tardieu 
Scale (MTS) for spasticity participants (or Unified Parkinson’s Disease Rating Scale (UPDRS) for 
rigidity participants) immediately before the testing began. For spastic and rigid subjects, the arm 
side with most affected was tested. For controls, the dominated side was chosen. 
 
33 
 
 
Table 2.1. Subject demographics 
 
 
2.3.4 EXPERIMENTAL METHODS  
 The values of 𝜃, 𝜔, 𝜏 from the PVRM were compared to those of the Biodex dynamometer. 
Prior to each test session, the PVRM modules were calibrated, and subject-specific surface EMG 
thresholds were established to monitor for voluntary biceps or triceps activation during passive 
movements. To do so, the participant was asked to perform an isometric contraction (70% of 
maximum voluntary isometric contraction) of biceps for three seconds and then triceps for three 
seconds while the EMG signals were collected. The skin contacting the sensors and electrodes 
 
 
Spasticity Rigidity Control 
ID S1 S2 S3 R1 R2 C1 C2 C3 C4 C5 
Gender M M M M M M M F M M 
Age (yrs) 33 56 56 71 51 61 56 58 55 25 
Tested Arm R L L R R R R R R R 
𝐿𝑓𝑜𝑟𝑒𝑎𝑟𝑚(cm) 24 23 25 24 24 26 23 22 24 24 
Height (cm) 182 175 180 177 178 185 172 165 177 181 
Weight (kg) 110 103 95 57 82 90 70 65 72 98 
Score a 4/2 3/2 3/2 2 2 - - - - - 
aThe scores for spasticity subjects are expressed in MAS/MTS, and the scores for rigidity subjects are expressed in 
UPDRS.   
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were prepared using the appropriate EMG setup guidelines [102] and all data were collected at 
1000Hz using the Delsys EMG Acquisition Software (EMGworks). All EMG data were detrended 
and filtered by (a) subtracting a constant offset (approximately 0.5 mV) of the EMG signals, (b) 
using a 60 Hz notch filter, (c) using a 4th order Butterworth band-pass filter from 10-400 Hz, and 
(d) rectifying the EMG signal. The subject-specific EMG thresholds for each muscle group was 
computed from the averages of these processed EMG data. Voluntary muscle contraction was 
defined as the instant when the EMG signal collected during a passive stretch test exceeded the 
thresholds for more than 0.5 seconds. 
 
Figure 2.5. Biodex setup for validating the PVRM measurements 
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 The dynamometer would rotate the participant’s arm via an adjustable custom-fabricated 
lever arm (Figure 2.5). The lever arm was used to 1) align the Biodex rotational axis to the elbow 
joint and 2) transfer all loads from the Biodex to the PVRM load cell. The participant’s lateral 
epicondyle was aligned with the rotating axis of the dynamometer by adjusting the custom lever 
arm length. The distance (𝐿𝑓𝑜𝑟𝑒𝑎𝑟𝑚) between elbow epicondyle and the load cell on the moving 
module was measured and recorded. The PVRM main module was attached on the participant’s 
upper arm, and the moving module was attached via Velcro to the end of the lever arm, allowing 
the PVRM to measure the same 𝜏 measured from the Biodex dynamometer. The PVRM moving 
module was fastened on the participant’s wrist, while the wrist was held in a neutral position 
(defined as the mid-point between supination and pronation) or as close to the neutral position as 
possible for participants with wrist contractions. All participants wore a wrist support brace (Yosoo 
Health Gear, Zhuang Junchao, China) to stabilize against unwanted wrist movements (the support 
brace was not included in any figures for clarity). 
 The Biodex dynamometer protocol and hardware were setup to perform passive elbow 
flexion and extension stretch tests tailored to each subject group. For spasticity and rigidity 
subjects, the trial started with the arm from the most comfortably flexed position and then passively 
at a slow speed (10°/sec for the biceps and triceps muscle to relax after the elbow flexion, since 
the degree of spasticity or rigidity may change after passive muscle movement [30]) to the most 
extended position comfortably possible. These most extended and flexed positions were 
determined for each subject by a certified clinician (author ST) prior to the test. Then the arm was 
flexed back to its determined flexed position at one of the three speeds: 75°/sec, 90°/sec, 120°/sec, 
which were typical flexion speeds for passive stretch tests of spasticity and rigidity [30]) chosen 
by a certified clinician (author ST). For spasticity, the flexion speed was chosen prior to the test 
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such that it was high enough to illicit a catch-release behavior while ensuring subject’s safety [103]. 
For rigidity, the flexion speed was also chosen prior to the test as the highest flexion speed while 
minimizing discomfort for the subject. Three trials were performed with three minutes of rest 
between trials to ensure muscle relaxation after each trial. For control subjects, the trial also started 
with the arm from the most flexed position and moved in extension at 45°/sec to the most 
comfortably extended position followed by a movement in flexion back to its initially flexed 
position at the same speed (45°/sec). Three trials were conducted at this speed. One trial at each 
speed were also performed at 75°/sec and 150°/sec to verify the PVRM’s accuracy at high 
movement speeds. 
The dynamometer performed passive movements following the above protocol while the 
PVRM, Delsys EMG, and Biodex collected data simultaneously. The Biodex sampled a 4-
component string of data at 100 Hz that included running time, angular position, angular velocity, 
and applied torque. The Biodex applied a nine-point moving average filter on the torque data to 
filter the effect of sudden acceleration or deceleration of the lever arm in the beginning and end of 
range of motion. For all Biodex torque data, the gravitational and inertial effect of the custom lever 
arm was removed from all torque readings. If voluntary muscle activation was detected, the trial 
was repeated. The data from the PVRM, Biodex, and EMG were later processed using MATLAB 
software (R2016a, MathWorks, Inc., Natick, Massachusetts, USA).  
 The PVRM and Biodex raw data were processed and analyzed during the subject’s arm 
flexion only, since the load cell cover plate of the moving module was designed for compression 
only. The PVRM and Biodex data were synchronized by using a cross-correlation between the 
signals, since a short time delay was observed between the recorded PVRM and Biodex data. 
Finally, the PVRM and Biodex data were truncated to compare the two data when the flexion 
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speed was constant. since the non-constant speed region displayed unwanted artifacts (e.g., high 
magnitudes of torque) of rapid acceleration and deceleration of the dynamometer. 
 To quantify the differences between the PVRM and Biodex data, the absolute residual as 
well as the percentage absolute residual between angular position, velocity and torque from the 
PVRM and Biodex during a given flexion cycle were computed. For each participant, the average 
and standard deviation of the absolute residual and the percentage absolute residual were computed 
for subject’s entire flexion range of motion. Then, the ensemble average and standard deviation of 
the absolute residual and of the percentage absolute residual for each test group (spasticity, rigidity, 
and controls) were computed.  
2.4 RESULTS 
 The PVRM and Biodex captured the joint kinematic and kinetic behavior of each subject 
group during passive arm movements (Figure 2.6). Spasticity participants displayed expected 
fluctuating elevated muscle tone marked by a distinct catch-release behavior during passive 
movement at the tested speeds (Figure 2.6(a,b)). Rigidity participants displayed uniformly elevated 
muscle tone without a catch-release behavior (Figure 2.6(c,d)). Healthy control participants did 
not demonstrate any increase in muscle tone even at high flexion speeds; the muscle tone for all 
control participants remained relatively similar and constantly low (less than 4Nm) during the 
flexion cycle (Figure 2.6(e,f)). For all subjects and trials, biceps and triceps muscles were inactive. 
The PVRM and Biodex data at slow and mediums stretch speed for control subject C4 were shown 
in Appendix A.  
 The PVRM measurements were similar to the gold standard Biodex measurements during 
the passive flexion, since the residuals for all measurements were between 1-13%. The error for 
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angular position and velocity measurements (less than 7 %) were smaller than torque 
measurements (less than 13%) (Figure 2.6). The torque measurement error was especially high for 
spasticity subjects. The standard deviation error of angular velocity measurement error was the 
lowest for all subjects.  
 
Table 2.2. Absolute residuals and percentages of residuals.  
 
 
Spasticity Rigidity 
Controls 
|Residuals| 
𝜃  (˚) 1.8 (2.7) 1.8 (2.9) 2.6 (2.4) 
𝜔 (˚/s) 4.6 (0.6) 1.1 (0.2) 1.0 (0.2) 
𝜏  (Nm) 0.2 (0.1) 0.1 (0.1) 0.2 (0.02) 
     
% |Residuals| 
𝜃  (%) 3.9 (5.4) 4.7 (6.6) 6.7 (5.0) 
𝜔 (%) 5.8 (0.55) 1.5 (0.23) 1.2 (0.15) 
𝜏  (%) 12.3 (3.0) 6.3 (3.2) 9.8 (1.2) 
The average and standard error (in parenthesis) for absolute and percentage residuals are shown above.  
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Figure 2.6. Comparison between the PVRM and Biodex data during a full trial (left column) and 
constant flexion speed (right column) for (a, b) spasticity subject S2, (c, d) rigidity subject R2, 
and (e, f) control subject C4. The constant flexion-speed-region (vertical dashed lines) in full 
trial plots was extracted. 
 
(a) (b) 
(d) (c) 
(e) (f) 
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2.5 DISCUSSION 
 The PVRM was able to characterize the arm movement of the three subject groups during 
passive flexion. The PVRM captured the spasticity patients’ catch-release behavior, a unique 
characteristic of spasticity. For example, a spasticity patient (S2 with MAS and MTS scores of 3 
and 2, respectively, demonstrated a distinct catch at a catch angle of 32˚ (t = 9.4 seconds) where 
the local maximum of torque (𝜏 = 4.6 Nm) was observed during flexion (Figure 2.7 (a)). The torque 
value at catch and average torque measurements during flexion agreed well with the torque values 
of spasticity patients with the same MAS and MTS score reported in the literature [43,90]. The 
catch occurred only when sufficient stretch speed (64˚/s for S2) was reached, since spasticity is 
stretch speed dependent. After the catch, a sudden drop in torque was observed, which manifested 
as release. This magnitude of the release was small since the dynamometer continuously exerted 
force on the subject’s arm. The release is more apparent when a clinician moves the patient’s arm, 
since the clinician would “release” or reduce the amount of force exerted on the patient’s arm to 
minimize risks for injury after the clinician feels the catch.  
The PVRM quantified expected characteristics of the rigidity patients: uniformly elevated 
muscle tone during passive arm movement (Figure 2.8 (c, d)). The maximum 𝜏 for the rigidity 
participants (7.2 Nm) was higher than that for the control participants (3.7 Nm) during passive 
flexion at constant speed. Unlike spasticity participants, the rigidity participants displayed no 
distinct catch-release behavior. This was expected, since rigidity is stretch velocity independent.  
 The PVRM accurately quantified the arm movement of the control participants at low, 
medium, and high flexion/extension speeds (Figure 2.9 (c, d)). Unlike spasticity or rigidity 
participants, control participants did not show elevated muscle tone or catch-release behavior 
during flexion even at high flexion/extension speeds (Figure 2.10 (c, d)). Any abrupt increase or 
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decrease in torque was due to high acceleration or deceleration that resulted from rapid change 
from flexion to extension or extension to flexion during multiple cycles on the Biodex.  
 The angular position and velocity measurements of the PVRM were sufficiently accurate 
for quantifying kinematic behavior of passive arm movement for all subject categories at various 
stretch speeds. The average absolute residual of angular position and velocity were no more than 
2.6˚ and 4.6˚/s, respectively, for all subject groups (Table 2.2). The magnitudes of these residuals 
are significantly smaller than the total range of motion (approximately 146˚ ~ 152˚ for males and 
females [104]) and average passive movement velocity during clinical assessments (45˚/s ~ 150˚/s 
[105]); the angular position and velocity residual was only 1.7% and 1.2% ~ 4%, respectively, of 
the total ROM and movement speed. These residuals were acceptable to be used in terms of 
analyzing kinematic behavior of human arm motion, since, even under ideal conditions, 
unremovable errors from human biomechanics study amount to a few degrees [106]. In addition, 
the standard deviation of the residuals for angular speed was low compared to angular position. A 
source of the small residual of angular position and speed was due to the difference of how the 
PVRM and Biodex measured 𝜃 and 𝜔. While the PVRM measured the elbow joint angle and speed 
by comparing IMU orientations of the forearm and upper arm, the Biodex measured the rotation 
of the forearm by reading and differentiating values from a rotary potentiometer at the axis of 
rotation. The PVRM could potentially provide a more accurate elbow joint angle than the Biodex, 
since the PVRM measured the relative motion of the forearm and upper-arm.  
 While the torque measurement was the least accurate compared to angular position and 
speed measurement, the torque measurement can be considered to be accurate enough to be used 
in quantifying the kinetic behavior of passive arm movement. The PVRM was able to detect catch-
release behavior for spasticity, uniformly elevated muscle resistance for rigidity, and low muscle 
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resistance for controls, despite the relatively high percentage residual (12.3% for spasticity, 6.3% 
for rigidity, 9.8% for controls) (Table 2.2). Thus, for our purpose of quantifying the characteristics 
of kinetic behavior of different subject categories, the PVRM provides sufficiently accurate torque 
measurement. The sources of error for torque measurement were due to 1) the misalignment 
between the rotational axis of the Biodex dynamometer and the participant’s elbow joint, and 2) 
the abnormal arm posture for spasticity participants. It was critical for the rotational axis of the 
Biodex dynamometer and the participant elbow joint to be aligned, since any misalignment caused 
a discrepancy between the trajectory of the subject arm movement and lever arm movement. This 
trajectory difference could have introduced unwanted moment (𝑀𝑢𝑤) created about the loadcell. 
The Biodex System 3 did not offer full adjustments of the seat height, making it difficult to align 
the Biodex rotational axis to the elbow joint. Abnormal arm posture of spasticity patients due to 
sustained muscle contractions also caused unwanted moment on the load cell. This was particularly 
evident for spasticity patient S1 with high MAS score, resulting in higher absolute residual for 
spasticity participants.  
 Certain limitations of the PVRM existed. The PVRM required a 5s calibration phase to 
ensure accurate kinematic measurements. The PVRM’s angular positional and velocity may be 
inaccurate at long running times due to the drifting of the IMUs. From our experiences, the drifting 
does not become an issue until five minutes after the calibration. Therefore, if assessments for 
multiple joints take longer than five minutes, then the PVRM should be recalibrated before 
continuing with assessments. Also, the uniaxial load cell could not remove unwanted moments 
introduced by the misalignment of the elbow joint and Biodex rotation axis.  
 For future work, a few improvements can be made to the hardware of the PVRM. First, a 
multi-axial load cell (i.e. 6 axis load cell) should be used to account for loads and moments from 
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all axes. Second, the ergonomics and user-experience can be improved by reducing the physical 
size of the PVRM modules for better comfort and reducing the setup time on patients with different 
arm geometries. With these improvements, the PVRM can be used to quantify various levels of 
spasticity and rigidity in a larger number of subjects to quantify and investigate biomechanical 
behavior of spasticity and rigidity during passive arm movement.  
 
2.6 CONCLUSIONS 
 The PVRM (Position, Velocity, and Resistance Meter) was designed and validated to 
quantify spasticity and rigidity patients about the elbow joint during passive arm movement. This 
validation study demonstrated that the PVRM’s measurements was able to quantify unique 
kinematic and kinetic behavior of spasticity and rigidity such as catch-release behavior and 
uniform elevation in muscle tone. The PVRM can help researchers gain additional insights into 
the quantification of spasticity and rigidity and allow clinicians to make more reliable assessments 
of these behaviors and severity levels.  
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CHAPTER 3: PRELIMINARY CLINICAL STUDY OF SPASTICITY AND RIGIDITY 
PATIENTS USING THE PVRM  
 
3.1 ABSTRACT  
 The goal of this study was to quantify and provide a database of joint kinematics and 
kinetics during passive stretching due to spasticity and rigidity in the upper-arm using a portable 
and validated measurement device, the PVRM (Position, Velocity, and Resistance Meter). 
Thirty-eight subjects with different levels of spasticity (n=15, Modified Ashworth Scale (MAS) 
scores 1-4) and rigidity (n=11, Unified Parkinson’s Disease Rating Scale (UPDRS) scores 1-3), 
as well as healthy age and gender matched controls (n=12) were tested using the PVRM. Key 
outcome parameters that quantify the joint kinematic and kinetic characteristics of spasticity and 
rigidity (e.g., increased muscle tone, stretch velocity dependency of muscle tone, presence of 
catch) were quantitatively defined and analyzed. Spasticity subjects demonstrated stretch 
velocity and MAS score dependent muscle tone marked by catch-release behavior, resulting in a 
non-constant torque profile, and a triangular stretch velocity profile across the range of motion. 
Rigidity subjects exhibited uniformly elevated muscle tone that was dependent on UPDRS score 
but independent of stretch velocity and showed no catch-release behavior. Healthy control 
subjects exhibited no increase in muscle tone and no catch-release behavior. While some of these 
characteristics of spasticity and rigidity have been qualitatively discussed in other literature, our 
study quantified these characteristics for spasticity and rigidity at different stretch velocities 
during both flexion and extension of the elbow. This study demonstrated that the PVRM can 
serve not only as a data collection tool to provide useful data for neuro-rehabilitation related 
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technologies and medical training simulators, but also as a clinical screening device to 
differentiate spasticity and rigidity from healthy muscle. 
3.2 INTRODUCTION 
 Hypertonicity is manifested by an abnormal increase in muscle tone (i.e., resistance to 
movements of relaxed muscles due to an outside force) during rest or passive stretching of the 
affected muscles [107]. The impaired ability to properly control descending pathways induce 
disordered spinal reflexes, causing involuntary movement in response to stimulus, and increased 
activity of muscle spindles, producing incorrect perception of muscle contraction [78]. 
 Spasticity and rigidity are two common types of hypertonicity [107]. Spasticity, caused 
by damaged motor neurons/descending reflex pathways, is characterized by a catch-release 
behavior (i.e., a sudden increase in muscle tone (“catch”) and a rapid decrease in tone (“release”) 
during passive movement), clonus (i.e., involuntary rhythmic series of muscle contractions and 
relaxations), and elevated muscle tone that is stretch-velocity dependent during passive 
stretching of the affected muscles [1,78]. Rigidity, caused by damage of basal ganglia/upstream 
pathways, is marked by a uniformly increased muscle that is stretch-velocity independent during 
passive movement [79][1,78]. There are two types of rigidity: lead-pipe rigidity (i.e., uniformly 
increased muscle resistance to passive movement throughout the entire range of motion) and 
cog-wheel rigidity (i.e., muscle resistance superimposed with tremor to passive movement) 
[107].  
 The Modified Ashworth Scale (MAS), a six-point scale that rates the degree of spasticity 
from 0 (healthy) to 5 (severely spastic), and the motor section of Unified Parkinson’s Disease 
Rating Scale (UPDRS), a five-point scale that rates the severity of rigidity from 0 (healthy) to 4 
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(severely rigid), are the most widely used rating scales for clinically assessing spasticity and 
rigidity, respectively [42,44]. For our study, we used a variant of MAS that rates from 0 to 5, 
rather than the original MAS that rates from 0 to 4 [42], These assessments involve a clinician 
manually moving the patient’s affected body segments at various stretch velocities and rating the 
patient’s hypertonicity in the five- or six-point scale. During this process, the clinician would 
subjectively feel the amount of muscle resistance [42,44]. In particular for spasticity assessment, 
the clinician would monitor the presence of catch-release behavior [42].  
 While these rating scales are convenient to use, there are some limitations: 1) inaccurate 
and unreliable assessments due to heavy reliance on rater’s subjective interpretation of the rating 
scales and past experiences, and 2) difficulty for inexperienced clinicians to learn the rating 
scales due to lack of practice patients and tools to experience different levels of spasticity and 
rigidity [53]. The inaccuracy and poor reliability has been reported by many researchers for 
spasticity and rigidity assessments [52,75,85–89]). Some claim the inter-rater and intra-rater 
reliability to be as low as 7.0% and 33.3%, respectively, for lower-extremity assessments if 
subjects with MAS score of 0 were excluded [53]. Interestingly, studies reported high accuracy 
(as high as 86%) for the upper-extremity assessments [42,108–110]. This dependency on the 
type of extremity may be due to the effect of limb weight that may affect the rating of the muscle 
tone [14]. Since the rating scales heavily depend on the assessor’s previous training and clinical 
experience, it is crucial for healthcare professional learners to gain enough hands-on assessment 
experience before entering the job site [111]. But current training mainly consists of inviting 
practice patients or asking students to mimic spasticity or rigidity and typically results in poor 
and inconsistent training outcomes and misrepresentation of true hypertonicity due to limited 
availability of practice patients [55]. 
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 Recently, some researchers have been developing medical training simulators that mimic 
different levels of spasticity or rigidity of real patients to complement current training practices 
[17,55–58,60,62,112–114]. However, there is a lack of a comprehensive database that quantifies 
the kinetic and kinematic behavior of spasticity and rigidity at all levels [17,60,112,113].  Such a 
database could serve as a valuable reference to fine tune the simulators for more realistic 
replications of spasticity and rigidity. 
 Researchers have developed measurement devices that quantify spasticity and rigidity 
with the intent of providing useful databases and objective assessment of hypertonicity 
[30,43,90–96]. However, these measurement devices had limitations that include inappropriate 
design for clinical deployment and narrow study scope. Some measurement devices were too 
impractical to be deployed in a clinical setting due to long setup time and bulky size [28,97]. 
Some studies lacked standardized testing protocol which led to inaccurate measurement [14,29]. 
Other studies had limited study scope that investigated exclusively only spasticity or rigidity, so 
the investigations of biomechanical differences between spasticity and rigidity were rarely made 
[14,29]. Even fewer studies quantified the biomechanics of different levels of severity of 
spasticity or rigidity [96]. Finally, some studies only focused on spasticity in biceps and not in 
triceps [14,29].  
 In the current study, we conducted a clinical test on human subjects with mild to severe 
levels of upper-arm (biceps and triceps) spasticity or rigidity at different stretch velocities using a 
compact, portable measurement device (the PVRM – Position, Velocity, and Resistance Meter) 
that can be attached quickly and with minimum setup requirements (Chapter 2). The PVRM 
consisted of small modules that can be attached to two adjacent body segments to measure 
kinematic and kinetic data, i.e. angular position and velocity, and the force applied by the 
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clinician to passively stretch the joint. This applied force is interpreted as muscle tone resistance 
felt by the clinician. From the PVRM raw data, key parameters that quantify relevant clinical 
symptoms of spasticity and rigidity, e.g. range of motion, average muscle resistance (tone), 
presence of catch, were defined and compared among all test subjects at four different stretch 
speeds (slow, medium, fast, and a velocity preferred by a trained clinician). Different stretch 
speeds were used to quantify the effect of stretch speed on muscle tone. For this study, a single 
clinician performed all testing to remove inter-rater variability. We focused on elbow flexion and 
extension muscle groups, since the MAS was reported to be most reliable for the upper-extremity 
by others [42,108–110]. The main goal of this study was to develop a preliminary database 
quantifying kinetic and kinematic muscle behavior during passive elbow flexion and extension 
for different levels of spasticity and rigidity.  
 
3.3 METHODS  
3.3.1 SUBJECT DEMOGRAPHICS 
 Thirty-eight subjects were tested (15 with spasticity, 11 with rigidity, and 12 age and 
gender matched healthy controls, Table 3.1). Thirteen spasticity subjects performed both flexion 
and extension trials. One spasticity subject did only flexion trials, and one spasticity subject did 
only extension trials. It is important to note that the spasticity subjects (n=13) who performed both 
movements did not necessarily exhibit the same severity level of spasticity during flexion as during 
extension (e.g., a subject with score of MAS 3 for extension may have had a score of MAS 2 for 
flexion). This unidirectional behavior of spasticity may be attributed to the difference of muscle 
fiber size between extensor and flexor muscles; extensor fiber area is known to be significantly 
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greater than flexor fiber area for type 2A and type 2B fibers [115], [116]. All spasticity subjects 
were post-stroke patients with hemiplegia. For rigidity subjects, all participants had rigidity in the 
flexor and extensor muscles and were diagnosed with Parkinson’s Disease. At least three 
participants were recruited for each level of spasticity (MAS 1-4) and rigidity (UPDRS 1-2).  Only 
two participants were tested for UPDRS 3 due to difficulty of finding subjects with this UPDRS 
score. Individuals at the most severe levels (MAS 5 and UPDRS 4) were not recruited since they 
have essentially no movement at the elbow.  
 Prior to testing, a certified neurologist (CMZ) rated the MAS or UPDRS scores. For 
spasticity and rigidity subjects, the more affected arm side was tested in this study. The arm with 
the dominant hand was tested for the healthy control subjects. Also, the clinician determined and 
noted whether the subject’s arm could be passively moved at fast stretch velocities (> 80˚/s). Wrist 
and arm contraction angles (i.e., contracted wrist pronation/supination angle and contracted elbow 
joint angle in resting position) were recorded. To note any physical, psychological, or medical 
effect on the muscle conditions, mental stress and physical fatigue, presence of infections, missed 
medications or new medications, history of injury on the tested arm in the past two weeks, presence 
of pain on the tested arm, and history of falls were also recorded. 
 All subjects satisfied the inclusion-exclusion criteria, and subjects with spasticity or 
rigidity were assessed using the MAS or motor section of the UPDRS for both arms. The inclusion 
criteria for the spasticity and rigidity subjects were: (a) 18-80 years of age, (b) in a stable 
neurological condition that caused spasticity or rigidity at the elbow joint, (c) no other significant 
neurological disorders in addition to the condition that caused spasticity or rigidity, (d) no history 
of musculoskeletal disorder at the elbow, and (e) can consent and follow command or be 
accompanied and consented by someone with a power of attorney. The inclusion criteria for the 
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healthy control participants were: (a) no history of abnormal hypertonic muscle behaviors or any 
neurological disease that would affect movement of the upper extremity, and (b) able to consent 
and follow command or be accompanied and consented by someone with a power of attorney. The 
exclusion criteria for all groups were: (a) history of paratonia, (b) recent injury to the arm, and (c) 
presence of tremor during passive stretch. The study was approved by the Institutional Review 
Boards at the University of Illinois College of Medicine and OSF HealthCare at Peoria and the 
University of Illinois at Urbana-Champaign. Testing was conducted at the OSF Healthcare Center 
at the Illinois Neurological Institute, Peoria, IL. Informed consent was obtained from all 
participants. 
Table 3.1. Subject demographics 
 
 
     Spasticity Rigidity Controls 
Movement Bidirectional 
Unidirectional 
(Flexion) 
Unidirectional 
(Extension) 
Bidirectional Bidirectional 
Total 
number of 
subjects 
13 1 1 11 12 
Score a  
(number of 
subjects) 
MAS 1 (3) 
MAS 2 (3) 
MAS 3* (4) 
MAS 4* (3) 
MAS 4 (1) MAS 2 (1) 
UPDRS 1 (5) 
UPDRS 2 (4) 
UPDRS 3 (2)  
– 
Age ± Stdev 
(years) 
62.6 ± 12.9 74 62 67.2 ± 6.7 60.4 ± 12.9 
Male: 
Female 
5:8 0:1 1:0 8:3 5:7 
a The scores for spasticity subjects are expressed in MAS, and the scores for rigidity subjects are expressed in 
UPDRS.   
* Six out of seven subjects with MAS 3 and 4 could not perform fast passive stretch tests.  
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3.3.2 PVRM – POSITION, VELOCITY, AND RESISTANCE METER 
 The PVRM collected kinetic and kinematic movement data (i.e., joint angular position 
(𝜃), velocity (𝜔), and muscle resistance (𝜏)), as well as monitoring muscle activity during 
clinical assessments (Figure 3.1). The PVRM consisted of two modules (moving, main) and two 
surface electromyography (EMG) electrodes for biceps and triceps. The moving module 
contained an inertial measurement unit (IMU) sensor (MPU-6050, InvenSense, California, USA) 
and a uniaxial load cell (LCM 300; Futek, California, USA). A wrist support brace (Yosoo 
Health Gear, Zhuang Junchao, China) was worn to stabilize the wrist. The moving module was 
strapped over the wrist support brace and was attached to the ulnar side of the wrist when 
assessing flexion and radial side when assessing extension. A custom cover plate for the load 
cell, where the clinician applied force, transmitted all of the applied force onto only the load cell. 
The main module contained a microcontroller (Micro; Arduino LLC; Italy), another IMU 
(similar as above), and a Bluetooth module (HC-05; Guangzhou HC Information Technology 
Co., Ltd.; China). The main module was strapped to the midpoint of the upper arm with the 
module facing laterally and aligned parallel to the humerus. Each EMG electrode was custom-
fabricated using a commercially-available bipolar EMG sensor electronics (MyoWare Muscle 
Sensor; Advancer Technologies; USA) with adjustable gain and two disposable electro-gel type 
EMG electrode patches (Arbo H124SG; Covidien; United Kingdom). The EMG measurement 
electrodes were attached to the midpoint of the biceps brachii and the long head of the triceps to 
ensure passive muscle status during the movement. A reference EMG electrode was attached 
over the clavicle. The raw PVRM data (i.e., sampled time, IMU data in quaternion form, load 
cell readings) and EMG data were sampled at 100 Hz and wirelessly transmitted to a tablet 
(Galaxy Tab E Lite; Samsung; Korea).  
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Before collecting the data, two calibration phases were needed: 1) a calibration to zero 
the load cell readings and align the local coordinates of the IMUs, and 2) an EMG calibration to 
determine the thresholds for voluntary biceps and triceps activation. The kinetic and kinematic 
calibration involved physically aligning and mating the moving and main modules so that the 
coordinate frames of IMUs were parallel (following the protocol defined in Chapter 2). The 
EMG calibration involved computing the EMG thresholds for voluntary muscle activation by 
recording a volitional degree of isometric contraction of the biceps for 3s and another for the 
triceps for 3s. The threshold was defined as the average of the recorded EMG signal during the 
3s contraction. Voluntary muscle contraction during a passive stretch test assessment was 
defined as the instance when the EMG signal exceeded these defined thresholds for more than 
0.5s.  
Figure 3.1. The PVRM modules configured for testing (a) flexion and (b) extension. 
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3.3.3 TESTING PROTOCOL 
 Two types of passive stretches (flexion and extension) were performed for each subject, 
except for those indicated in Table 3.1. Passive flexion was performed such that the plane of arm 
movement was perpendicular to the ground (Figure 3.1). Passive extension was performed with 
the shoulder abducted close to 90˚ while the elbow rested on a height-adjustable table such that 
the plane of forearm movement was parallel to the ground (Figure 3.1). This extension arm 
configuration was necessary to allow the clinician to properly apply force on the PVRM load cell 
cover plate. Otherwise, gravity would constantly pull the subject’s arm away from the clinician’s 
hand, making the exertion of force on the load cell difficult especially for control subjects with 
no muscle resistance. In addition, the subject’s forearm had to be supported to be parallel to the 
ground. An anatomically neutral wrist position (or a position closest to neutral position) was 
chosen for the participant since spasticity patients with wrist contractions could not pronate or 
supinate their forearms. 
 For each type of passive stretch test, four stretch speeds were tested: slow (5˚/s - 20˚/s), 
medium (20˚/s - 80˚/s), fast (> 80˚/s), and clinician’s preferred speed (> 30˚/s). Preferred speed 
was the stretch speed at which our clinician-investigator (author CMZ) would typically stretch 
the subject’s arm during a clinical evaluation of spasticity or rigidity. Three trials were 
performed for each speed. Thus, a total of 24 trials (12 flexion and 12 extension) were performed 
for all subjects with the following exceptions: two unidirectional spasticity subjects who only 
performed 12 trials each, and six severely spastic subjects (MAS 3 or 4) who could not perform 
fast stretch speed trials due to severely increased tone and/or permanent contractures. These six 
subjects performed only slow, medium, and preferred stretch speeds (a total of 18 trials). For all 
subjects, flexion trials were performed first starting with slow stretch speed followed by medium, 
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fast, and preferred stretch speed. Afterwards, extension trials were performed starting with the 
same stretch speed order as flexion trials. For each trial, the clinician passively stretched the 
subject’s arm until full range of motion was reached. The trial was repeated if the stretch speed 
was too high or low, or either muscle group was voluntarily activated. After each trial, a rest 
period of 30-60 seconds was given to ensure muscle relaxation between trials.  
 
3.3.4 DATA PROCESSING 
 The raw PVRM data from the tablet were later downloaded and post processed in a PC 
using Python scripts to compute angular position (𝜃) and velocity (𝜔), and muscle resistance (𝜏) 
data using the same approaches as defined in Chapter 2. To compute 𝜃, the angular difference 
between the x-axes of IMU 1 (IMU of moving module) and IMU 2 (IMU of main module) was 
computed using the dot product of the two vectors) (Figure 3.1). 𝜔 was found by subtracting 
gyroscopic readings of IMU 1 from 2. 𝜏 was equivalent to the applied torque (exerted by the 
clinician) with the gravitational and inertial effects of the moving forearm removed. The applied 
torque was defined as the product of the load cell reading and the distance between elbow joint 
and the load cell. To remove gravitational and inertial effect of the moving forearm on the torque 
measurement, the mass of the moving body segment (wrist and forearm), distance from the 
elbow joint to the center of mass of the moving body segment, and rotational inertia of the 
moving body segment about the elbow joint or Z-axis were estimated using known 
anthropometric equations [101] given the subject’s gender, body mass, and height. The 
gravitational effect was only removed for data during passive flexion, since the movement plane 
during passive extension was parallel to the ground. The PVRM data’s accuracy 
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(% |𝑅𝑒𝑠𝑖𝑑𝑢𝑎𝑙| 𝑜𝑓 𝜃,𝜔, 𝜏 = 5.1%, 2.8%, 9.5%) was demonstrated to be sufficient in a validation 
study where the PVRM values were compared to a gold standard dynamometer (Biodex System 
3) in previous studies (Chapter 2, Song et al. 2017, 2018). 
The processed PVRM data were filtered and truncated to remove unwanted noise and to 
analyze the data only relevant to movement. The angular position and velocity data were filtered 
via an analog lowpass filter with a cutoff frequency of 50 Hz. The torque data from the load cell 
were filtered using a 4th order Butterworth lowpass filter with a cutoff frequency of 10 Hz. The 
filtered PVRM data were then truncated. The start of the limb movement (tstart) was defined as 
the time when the movement velocity was above 5˚/s and when the change in torque across a 
unit sample time (
∆ 𝑇𝑜𝑟𝑞𝑢𝑒
∆ 𝑇𝑖𝑚𝑒
) was above 0.1 Nm/s. End of the movement (tend) was defined as the 
time when the movement velocity was below 5˚/s. Change in torque across unit time was not 
used for defining tend, since the arm with spasticity or rigidity exhibited changes in torque even at 
the end of movement. 
A robust catch definition was introduced using both kinetic (muscle resistance: 𝜏) and 
kinematic (angular position, velocity, and acceleration: 𝜃,𝜔, 𝛼, respectively) data to quantify the 
catch-release behavior of spasticity (Figure 3.2). The quantitative definition of catch was 
investigated by referring to the clinical definition of a catch: a catch is defined as a sudden 
appearance of increased muscle activity in response to a fast passive stretch, which leads to an 
abrupt reduction in velocity (1st criterion) and sudden increased resistance (2nd criterion), at a 
certain angle before maximum range of motion (ROM) was reached (3rd criterion) [119,120]. 
Therefore, we defined a catch as the instance when: the forearm was at maximum deceleration 
(1st criterion), the torque peaked at a local maximum and exceeded a threshold that was trial 
56 
 
specific (threshold = 1.25 × standard error of resistance during one trial) (2nd criterion), and the 
angular position was below 90% of the subject’s maximum ROM (3rd criterion) (Figure 3.2). The 
release was defined as the instance of the first local minimum of torque after the catch.  
To comprehensively characterize each test group, conceptual joint kinetic and kinematic 
patterns for each group were developed (Figure 3.3(a)). Healthy arms were expected to exhibit 
low muscle tone at all stretch speeds and a trapezoidal stretch velocity profile that consisted of 
three regions (acceleration, constant velocity, and deceleration). Rigid arms were expected to 
demonstrate uniformly elevated muscle tone that was stretch velocity independent and had no 
catch-release behavior. Also, rigidity would display a trapezoidal stretch velocity profile that 
resembled the profile of a healthy arm but with smaller velocity magnitude. Spastic arms would 
display a catch-release behavior and elevated muscle tone especially at fast and clinician’s 
preferred stretch velocities. The presence of a catch-release behavior would cause the muscle 
tone to vary dramatically across the range of motion. Also, passive stretching of a spastic arm at 
high stretch speeds would resemble a triangular stretch velocity profile. This was because the 
clinician would rapidly accelerate the arm to elicit the catch-release behavior and then abruptly 
decelerate the arm once the end of range of motion was near. It is important to note that, at slow 
stretch speeds or for mildly spastic arms, spastic behavior would exhibit only small increase in 
muscle tone without a catch due to the stretch speed dependency of spasticity [103]. 
A list of outcome parameters that comprehensively quantify passive movement were 
defined (Table 3.2). To quantify the magnitude of muscle tone, average muscle resistance (𝜏𝑎𝑣𝑔), 
maximum muscle resistance (𝜏𝑚𝑎𝑥  ), and exerted energy normalized to the range of motion 
(𝐸𝑛𝑜𝑟𝑚) were defined. Also, two additional parameters for quantifying kinetic behavior were 
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defined: i) stiffness (𝑆) and ii) the standard deviation of stiffness (𝑆𝑠𝑡𝑑). 𝑆𝑠𝑡𝑑 could be used to 
quantify the degree of fluctuations in muscle tone, since the standard deviation (i.e. variations) of 
the torque change is proportional to fluctuations in muscle resistance. It was hypothesized that 
𝑆𝑠𝑡𝑑 would be higher for spasticity subjects due to higher degree of torque changes due to 
presence of catch. To quantify joint kinematic behavior for control and rigidity subjects, the 
angle at the end of acceleration region (𝜃𝜔_𝑟𝑖𝑠𝑒), angle at the end of constant velocity region 
(𝜃𝜔_𝑓𝑎𝑙𝑙), and the average velocity at the constant velocity region (𝜔𝑎𝑣𝑔) were introduced to 
characterize the trapezoidal stretch velocity profile. To quantify joint kinematic behavior for 
spasticity subjects, maximum stretch velocity (𝜔𝑚𝑎𝑥 ) and angle at maximum stretch velocity 
(𝜃𝜔_𝑚𝑎𝑥) were defined to characterize the triangular stretch velocity profile and identify the 
highest velocity point. To evaluate the catch-release behavior of spasticity subjects, parameters 
relating to catch angle and torque (𝜃𝑐𝑎𝑡𝑐ℎ , 𝜏𝑐𝑎𝑡𝑐ℎ), release angle and torque (𝜃𝑟𝑒𝑙𝑒𝑎𝑠𝑒 , 𝜏𝑟𝑒𝑙𝑒𝑎𝑠𝑒), 
acceleration at catch (𝛼𝑐𝑎𝑡𝑐ℎ, 𝛼𝑟𝑒𝑙𝑒𝑎𝑠𝑒 ), and torque at the end of the post-release region 
(𝜏𝑝𝑜𝑠𝑡−𝑟𝑒𝑙𝑒𝑎𝑠𝑒) were established (Figure 3.3(a)). The post-release region started from the onset of 
release until the end of ROM. Finally, to quantify stretch speed dependent muscle tone, two 
parameters were developed: difference of muscle resistance between slow and clinician’s 
preferred stretch speed (Δ𝜏) and the stretch speed dependency of muscle resistance (SSD). For 
Δ𝜏, muscle resistance at the preferred stretch speed was used due to the six spasticity subjects 
who could not perform the fast stretch speed trials. SSD was defined to be the slope of the  𝜏𝑎𝑣𝑔 
vs. 𝜔𝑎𝑣𝑔 plot, where higher SSD indicated greater velocity dependency (Figure 3.3(b)). Seven of 
the outcome parameters were designated as key outcome parameters that succinctly characterize 
each subject category was also identified (Table 3.2). These key outcome parameters quantified 
the range of motion (𝜃𝑅𝑂𝑀), catch angle (𝜃𝑐𝑎𝑡𝑐ℎ), average stretch velocity (𝜔𝑎𝑣𝑔), maximum 
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stretch velocity (𝜔𝑚𝑎𝑥), average muscle resistance (𝜏𝑎𝑣𝑔), maximum muscle resistance (𝜏𝑚𝑎𝑥), 
and difference in muscle resistance between preferred and slow test speeds (Δ𝜏). Non-key 
outcome parameters were metrics that were not included in the key outcome parameters. 
Ensemble sample averages of the outcome parameters of spasticity, rigidity, and control subjects 
were computed to investigate inter-group and intra-group characteristics. 
 
 
Figure 3.2. Quantitative definition of catch-release behavior.  
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Figure 3.3. Conceptual graphs comparing healthy, spastic, and rigid muscle behavior during passive 
movement at fast and slow stretch speeds. (a) Muscle resistance (τ) and stretch velocity (ω) profile and (b) 
stretch speed dependency (SSD) of muscle resistance are shown. 
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Table 3.2. Definitions and relevant clinical feature of outcome parameters. 
 Symbol Definition 
Relevant clinical feature 
(subject category) 
Key Outcome 
Parameters 
 𝜃𝑅𝑂𝑀  (˚) Range of Motion (ROM) ROM (All) 
𝜃𝑐𝑎𝑡𝑐ℎ  (˚/𝑠) Catch angle 
Catch – release behavior 
(Spasticity)  
𝜔𝑎𝑣𝑔 , 𝜔𝑚𝑎𝑥  (˚/𝑠) 
Average and maximum velocity for a 
trial 
Trapezoidal (Control & 
Rigidity) and Triangular 
(Spasticity) velocity profile  
𝜏𝑎𝑣𝑔 , 𝜏𝑚𝑎𝑥 (𝑁𝑚) Average and maximum 𝜏 for a trial Muscle tone (All) 
Δ𝜏 (𝑁𝑚) Δ𝜏 = 𝜏𝑎𝑣𝑔
𝑝𝑟𝑒𝑓𝑒𝑟𝑟𝑒𝑑 − 𝜏𝑎𝑣𝑔
𝑠𝑙𝑜𝑤  
Velocity dependency of tone 
(All) 
Non-Key 
Outcome 
Parameters 
𝜃𝜔_𝑟𝑖𝑠𝑒(˚) 
𝜃𝜔_𝑓𝑎𝑙𝑙 (˚) 
𝜃 when 𝜔 exceeds 𝜔𝑎𝑣𝑔for the first 
time 
𝜃 when 𝜔 is less than 𝜔𝑎𝑣𝑔  for the last 
time 
Trapezoidal velocity profile 
(Control & Rigidity) 
𝜃𝑚𝑎𝑥_𝜔(˚) 𝜃 at 𝜔𝑚𝑎𝑥  
Triangular velocity profile 
(Spasticity) 
𝐶𝑎𝑡𝑐ℎ % Catch frequency = 
# 𝑜𝑓 𝑐𝑎𝑡𝑐ℎ𝑒𝑠
𝑡𝑜𝑡𝑎𝑙 # 𝑜𝑓 𝑡𝑟𝑖𝑎𝑙𝑠
× 100 
Catch – release presence 
(Spasticity) 
𝜃𝑟𝑒𝑙𝑒𝑎𝑠𝑒  (°) 
𝛼𝑐𝑎𝑡𝑐ℎ , 𝛼𝑟𝑒𝑙𝑒𝑎𝑠𝑒  (˚/s2) 
𝜏𝑐𝑎𝑡𝑐ℎ , 𝜏𝑟𝑒𝑙𝑒𝑎𝑠𝑒 (𝑁𝑚) 
𝜃, 𝛼, 𝜏 at catch and release 
Catch – release behavior 
(Spasticity)  
𝜏𝑝𝑜𝑠𝑡−𝑟𝑒𝑙𝑒𝑎𝑠𝑒  (𝑁𝑚) 
𝐸𝑝𝑜𝑠𝑡−𝑟𝑒𝑙𝑒𝑎𝑠𝑒  (𝐽) 
Average of 𝜏 across post-release 
region. 
 𝐸𝑝𝑜𝑠𝑡−𝑟𝑒𝑙𝑒𝑎𝑠𝑒 =
∫ 𝜏 𝑑𝜃
𝜃=𝑅𝑂𝑀
𝜃=𝜃𝑟𝑒𝑙𝑒𝑎𝑠𝑒
(𝑅𝑂𝑀−𝜃𝑟𝑒𝑙𝑒𝑎𝑠𝑒)
 
Catch – release behavior 
(Spasticity) 
𝐸𝑛𝑜𝑟𝑚  (𝐽) 
Applied energy normalized to ROM = 
Area under the 𝜏 vs 𝜃  (J)
𝑅𝑂𝑀 (𝑖𝑛 𝑟𝑎𝑑)
 = 
∫ 𝜏 𝑑𝜃
𝜃=𝑅𝑂𝑀
𝜃=0
𝑅𝑂𝑀
 
Muscle tone (All) 
𝑆 (𝑁𝑚/˚) Stiffness Muscle tone (All) 
 𝑆𝑎𝑣𝑔 , 𝑆𝑚𝑎𝑥(𝑁𝑚/°)  
Average and maximum of 𝑆 =
Δ𝜏
Δ𝜃
 for a 
trial 
Muscle tone (All) 
𝑆𝑠𝑡𝑑  (𝑁𝑚/°) Standard deviation of 𝑆 for a trial Muscle tone fluctuation (All) 
SSD (𝑁𝑚 °/𝑠⁄ ) Slope of 𝜏𝑎𝑣𝑔  𝑣𝑠 𝜔𝑎𝑣𝑔   
Velocity dependency of tone 
(All) 
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3.4 RESULTS AND DISCUSSIONS 
 This study quantified the behavioral features of spastic, rigid, and healthy muscles 
(Figure 3.3) as observed clinically in literature [1,42,44,78,79,84]. The observed characteristics 
for the rigidity subjects were 1) uniformly elevated muscle tone across the range of motion as 
compared to healthy controls, 2) muscle tone proportional to UPDRS score with little to no 
stretch velocity dependency, 3) trapezoidal stretch velocity profiles with lower average stretch 
velocities than controls, 4) no presence of catch-release behavior, and 5) no significant reduction 
of range of motion (ROM) (Figures 3.3, 3.4(a), Tables 3.5,3.6). Two cases of anomalous 
behavior were observed for rigidity trials (Figure 3.5(a): 1) excessive perturbation at the start of 
range of motion, and 2) increasing resistance across the range of motion). Observed 
characteristics of the spasticity subjects were 1) varying muscle tone across the range of motion 
due to presence of catch, 2) increased muscle tone that was stretch velocity dependent, 3) 
triangular stretch velocity profiles marked by high acceleration and deceleration, 4) occasional 
presence of catches that occurred at mid-point of ROM and at fast or preferred stretch velocities, 
and 5) kinetic and kinematic behaviors seen from only severely spastic subjects such as 
significantly reduced ROM, reduced stretch velocity, and more frequent catch-release behaviors 
(Figures 3.3, 3.4(b), 3.6, Tables 3.7-3.10). Spasticity without catch presence resembled rigidity 
especially at slow or medium stretch velocities (Figure 3.5(c,d)). While some of these 
characteristics of rigidity and spasticity were observed in literature [105,121,122], our study 
quantified these characteristics from slow to fast stretch speeds for different levels of spasticity 
and rigidity in extensor and flexor muscle groups.  
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3.4.1 RIGIDITY 
Generally, rigidity subjects exhibited elevated muscle resistance (with minor 
disturbances) that was constant across the range of motion. Outcome parameters relating to 
muscle tone (𝜏𝑎𝑣𝑔, 𝜏𝑚𝑎𝑥, 𝐸𝑛𝑜𝑟𝑚) were all higher for rigidity subjects than healthy controls at all 
stretch speeds. For example, subjects with UPDRS score of 1 showed three to five times more 
average muscle resistance (𝜏𝑎𝑣𝑔), and subjects with UPDRS score of 3 showed seven to ten times 
more average muscle resistance at all stretch velocities during passive extension and flexion 
(Table 3.5, 3.6). Most rigidity subjects displayed this increased tone from the beginning of the 
range of motion, indicating that the muscle tone was present during rest (Figure 3.4(a)). This 
indirectly confirms literature’s findings that elevated tone of rigidity can be attributed to 
abnormal increase in elasticity and stiffness of muscles that are present during rest [28–
31,45,46,123–125]. This increase in elasticity implies that rigidity could originate from changes 
in intrinsic properties of joints, tendons, and muscles [126]. Thus, based on our results, rigidity 
may be partially affected from changes in passive properties of joints and soft tissues. Other 
studies have shown that another contributing factor for rigidity may be hyperexcitability of 
stretch reflex [126,127].   
This muscle tone of rigidity subjects was proportional to the UPDRS score but 
independent to stretch speed. Severe rigidity subjects (UPDRS 3) displayed almost two to three 
times as much muscle tone (𝜏𝑎𝑣𝑔, 𝜏𝑚𝑎𝑥, 𝐸𝑛𝑜𝑟𝑚) than mild rigidity subjects (UPDRS 1) at all 
stretch velocities during passive flexion and extension. Also, muscle tone of rigidity subjects was 
independent of stretch speed (Figure 3.4(a), Tables 3.5, 3.6). The stretch speed dependency of 
muscle tone (SSD) of rigidity subjects were significantly smaller in magnitude compared to 
spasticity subjects (Figure 3.6). All rigidity subjects had a small positive value of SSD close to 
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zero (0.035 - 0.051 Nm/(˚/s)) during extension, indicating only a slightly positive stretch speed 
dependency (hypersensitivity) of tone (Figure 3.6). Interestingly, flexion test results contained 
only a small negative value of SSD close to zero (-0.016 - 0.028 Nm/(˚/s)), indicating small 
negative stretch speed dependency (hyposensitivity) of tone (Figure 3.6). In addition, SSD 
depended only slightly on UPDRS scores: SSD of higher UPDRS score subjects was more 
positive during extension but more negative during flexion (Figure 3.6). Other studies also found 
this directional dependency of rigidity’s sensitivity to stretch speed [28,40,41]. Nevertheless, the 
magnitudes of these SSD were much smaller (175% and 910% smaller during extension and 
flexion trials, respectively) compared to the spasticity subjects (Figure 3.6). Thus, while a small 
directional dependency (i.e., hyposensitive velocity dependency during flexion while 
hypersensitive velocity sensitivity during extension) of muscle tone was observed, the muscle 
tone dependency on stretch velocity of rigidity was minimal compared to spasticity. 
Trapezoidal stretch velocity profiles of rigidity subjects had lower average and maximum 
stretch velocity (𝜔𝑎𝑣𝑔, 𝜔𝑚𝑎𝑥) than healthy subjects for fast and preferred stretch velocity trials 
by approximately 20˚/s during flexion and extension (Figure 3.4(a), Tables 3.5, 3.6). 
Interestingly, higher UPDRS score did not correlate with lower 𝜔𝑎𝑣𝑔, 𝜔𝑚𝑎𝑥, indicating that the 
stretch velocity did not reduce significantly due to increased muscle tone (Figure 3.4(a), Tables 
3.5, 3.6). In addition, the stretch velocity profiles for the mild rigidity subjects were similar to 
those for the healthy control subjects (Figure 3.4). Ultimately, the stretch velocity profile of rigid 
arms resembled that of healthy arms in shape but smaller in magnitude.  
No significant reduction of ROM was observed for rigidity subjects since none displayed 
permanent contractures. The range of motion (ROM) of all rigidity subjects were similar to the 
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control subjects during extension and flexion (Figure 3.4, Tables 3.5, 3.6). The ROM for all 
rigidity subjects was only smaller than the controls by 17% during extension and 5% during 
flexion (Tables 3.5, 3.6). Others have also reported that rigidity subjects did not show significant 
reduction of ROM [25].  
There were two cases of unexpected kinetic behaviors for rigidity subjects: i) excessive 
perturbations of the muscle resistance, and ii) linearly increasing muscle resistance across range 
of motion (Figure 3.5(a)). This overshooting of muscle resistance occurred in only 3 % of the 
total test trials and appeared only in the beginning of ROM (Figure 3.5(a)). These perturbations 
may be due to excessive tilting action introduced by the clinician, increasing unwanted moments 
about the load cell. For 13% of all rigidity test trials, resistance was linearly proportional to 
angular position (Figure 3.5(a)). This linearity may suggest that the changes of elasticity and 
stiffness is a function of angular position for some rigidity subjects. Other studies have reported 
similar findings [128]. The changes in intrinsic and passive muscle properties may be more 
severe towards the end of ranges of motion or longer muscle stretch length. Interestingly, the 
slope of the best fitting line of muscle resistance increased was proportional to the UDPRS score 
(Figure 3.5(a)). Apart from these irregular kinetic behaviors, the majority (87% of all rigidity test 
trials) displayed no major perturbation of resistance or linearly increasing muscle tone across the 
range of motion. 
 
3.4.2 SPASTICITY 
Spasticity subjects demonstrated elevated and varying muscle tone across the range of 
motion. For example, the average and peak muscle resistance for spasticity subjects at average 
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stretch velocities were 4.8Nm and 6.8Nm, respectively, higher than control subjects during 
passive extension (Table 3.7). This elevated muscle tone can be attributed to stretch reflex 
hyperexcitability and muscle contractures that alter the intrinsic mechanical properties of 
muscles [1,2,71,73,78,129]. 𝑆𝑠𝑡𝑑, a parameter that describes the degree of muscle tone variation, 
was greater for spasticity subjects than rigidity and control subjects by almost two to three times, 
respectively, during passive extension and flexion (Tables 3.7, 3.9). This variation of tone can be 
attributed to the presence of catch-release behavior, since the catch induces a rapid increase in 
tone and a sudden drop in tone. Note that the magnitude of release may be dependent on the 
clinician’s stretching technique; the clinician slowed the movement once a sufficient resistance 
(i.e., catch) was felt. From our previous study (Chapter 2) that elicited a catch-release behavior 
using a dynamometer (Biodex) that continuously flexed the subject’s arm at a constant 
acceleration until constant speed was reached, we observed that the magnitude of release for a 
MAS 3 subject was not as severe as the MAS 3 subjects in this study. Thus, if many raters are 
involved in future studies, consolidating on a uniform rating technique may be important to 
minimize the inter-rater variability.  
Muscle tone of spasticity was stretch speed dependent (Figures 3.4(b), 3.6, Tables 3.7, 
3.9). These subjects had positive SSD that was greater than rigidity subjects by 160% during 
extension and 532% during flexion (Figure 3.6).  In literature, this stretch velocity dependency 
has been found in other joints as well, e.g. knee and ankle [130,131]. Ultimately, spasticity was 
marked by hypertonia during passive movement and was hypersensitive to changes in stretch 
velocity. This supports the claim that spasticity can generally be regarded more as a viscous 
component of muscle tone (artifact of neuromodulated behavior) rather than an elastic 
component (artifact of intrinsic changes of muscle tissues and tendons) due to its dependency on 
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stretch velocity rather than position [19,30]. Interestingly, MAS 1 subjects had similar SSD to 
UPDRS 2 & 3 subjects during extension, suggesting that there is little biomechanical difference 
between MAS 1 and UPDRS 2-3. Also, the MAS 1 subjects displayed an SSD like the controls 
during flexion, indicating that very mild spasticity kinetically behaves similarly to healthy 
controls for extensor muscles. Therefore, stretch speed dependency of muscle resistance may be 
a valuable differentiating factor to separate spasticity from rigidity and controls except for very 
mild cases of spasticity. 
The stretch velocity profile for spasticity subjects resembled a triangular or a convex 
parabolic shape, where the maximum stretch velocity (vertex of parabola) had to be achieved as 
fast as possible to elicit a catch-release behavior (Figure 3.4(b)). The maximum velocity was 
always reached before the catch occurred for all spasticity subjects. In addition, the stretch 
velocity profile contained another local maximum after the release for mild spasticity subjects 
(MAS 1-2), indicating that the stretch velocity increased slightly after the release (Figure 3.4(b)). 
For severe spasticity subjects (MAS 3-4), the stretch velocity would either not increase at all or 
increase only slightly (Figure 3.4(b)). This could be due to the clinician’s response of 
accelerating the limb to maintain a constant resistance after the release had occurred. For mild 
spasticity subjects, the magnitude of resistance during post-release region was lower than severe 
spasticity subjects, so the clinician was able to increase the stretch velocity more for mildly 
spastic arms than for severely spastic arms (Figure 3.4(b)). Hence, the stretch velocity profile of 
spastic arm involved a small increase of stretch velocity after the release, but the overall stretch 
velocity profile followed a triangular shape.  
Another behavior of spasticity was the occasional presence of catch at the mid-point of 
ROM (Figure 3.4(b), Tables 3.7-3.10). Catches occurred more frequently (26.2% - 57.7% of all 
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trials) at fast and preferred stretch speeds and none at slow stretch speeds. For medium stretch 
speed, there was high catch percentage during extension (40%) and none during flexion (Tables 
3.7, 3.9). While this intermittent presence of catch-release behavior among spasticity subjects 
was reported by other researchers as well [132], our study is the first to report the frequency of 
catch among spasticity subjects. Most of the catches for spasticity subjects occurred 
approximately at the mid-point of the ROM. While the 𝜃𝑐𝑎𝑡𝑐ℎwas smaller for higher MAS scored 
subjects, these catches occurred consistently at the mid-point of the range of motion 
(
𝜃𝑐𝑎𝑡𝑐ℎ
𝑅𝑂𝑀
× 100% ≅  50%) for all spasticity subjects (Figure 3.4(b), Tables 3.8, 3.10). 𝜃𝑐𝑎𝑡𝑐ℎ for 
MAS 4 subjects was 61% of ROM during extension and 53% of ROM during flexion, and 𝜃𝑐𝑎𝑡𝑐ℎ 
for MAS 2 was 51% of ROM during extension and 53% of ROM during flexion (Tables 3.8, 
3.10). While we confirmed the reporting of other studies that catches occur earlier (i.e., smaller 
catch angle) for more severe spasticity subjects [132], we found that the relative catch location to 
the total ROM (% ROM) is similar for all spasticity subjects because the severely spastic 
subjects had less ROM. Catch occurring at half of ROM may be due to the need for clinician to 
accelerate sufficiently in the beginning to reach the velocity for eliciting catch while decelerating 
at the end of ROM to minimize risks of injury.  
Release occurred immediately after the catch and displayed less muscle resistance, 
whereas the post-release region contained slightly smaller or larger muscle resistance than 
resistance at release (/𝜏𝑟𝑒𝑙𝑒𝑎𝑠𝑒) (Figure 3.4(b), Tables 3.8, 3.10). For all spasticity subjects, the 
release occurred after catch within 10˚ during extension and 12˚ during flexion (Figure 3.4(b), 
Table 3.8, 3.10). In addition, the torque at release was significantly lower than torque at catch. 
For example, 𝜏𝑟𝑒𝑙𝑒𝑎𝑠𝑒 was lower than 𝜏𝑐𝑎𝑡𝑐ℎ for all spasticity subjects by 76 % during extension 
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and 33% during flexion at preferred stretch speed (Table 3.8, 3.10). Also, the magnitude of 
deceleration at release was much smaller than that of catch, since only a small amount of 
resistance prevailed after catch. For example, the magnitude of deceleration was reduced by 
105% during extension and 110% during flexion at preferred stretch speed (Tables 3.8, 3.10). 
After the release, the post-release region contained higher muscle tone than 𝜏𝑟𝑒𝑙𝑒𝑎𝑠𝑒 for the 
severe spasticity subjects by 19% during extension and 4% during flexion (Figure 3.4(b), Tables 
3.8, 3.10). Ultimately, immediately after catch, release was found where the magnitude of 
deceleration and resistance greatly decreased.  
Different kinetic and kinematic characteristics were displayed by severely spastic 
subjects (MAS 3-4). First, significantly reduced range of motion (ROM) was seen for these 
subjects (Tables 3.7, 3.9). Also, the ROM of these spasticity subjects was lower in mildly spastic 
subjects by 32 % during extension and 33 % during flexion. This reduction of ROM was mainly 
attributed to paresis or permanent muscle contraction while spasticity was an indirect cause. 
Severe spasticity and prolonged immobility increases the elastic stiffness of muscles by altering 
the properties of muscles and connective tissues, ultimately causing permanent muscle 
contraction [22,71–73,83,133]. The muscle tone for MAS 4 subjects who had the most reduction 
of ROM exhibited less muscle tone than MAS 3 subjects particularly during flexion, since the 
clinician had difficulty passively flexing the arm and exerting greater torque as the end of range 
of motion was reached very early. Second, the maximum stretch velocity (𝜔𝑚𝑎𝑥) for the severely 
spastic subjects were lower than mild subjects (Figure 3.4(b), Tables 3.7, 3.9). For example, the 
𝜔𝑚𝑎𝑥 of MAS 4 was greater than MAS 1 by +56% during extension and +88% during flexion 
(Tables 3.7, 3.9). This reduction of stretch velocity is due to the higher degree of muscle tone 
existent among severely spastic subjects. While it was difficult to reach faster stretch velocities, 
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nevertheless the clinician was able to elicit a catch from these subjects, which indicated that the 
dependency of spasticity to stretch velocity becomes significantly more apparent for high MAS 
subjects. Third, catches were more frequently elicited for severely spastic subjects than mildly 
spastic subjects during flexion and extension. While the catch percentage was 22% during 
extension and 12% during flexion for mild spasticity subjects, the catch percentage was 47% 
during extension and 23% during flexion for severe spasticity subjects (Tables 3.7, 3.9). Again, 
this may be because severe spasticity was more sensitive to stretch velocity. In addition, for 
severe spasticity subjects, the muscle resistance increased slightly during the post-release region. 
This coincides well with the qualitative description for the MAS 3 and 4 grades in the MAS table 
[42]. 
Like rigidity, a few cases of irregular behavior were observed for the spasticity subjects 
(Figure 3.5(b-d)). First, 2% of flexion trials demonstrated signs of excessive releases in which 
the moving forearm extends by a small amount during release (Figure 3.5(b)). We hypothesize 
that behavior was due the rater’s technique: at the onset of release, the clinician momentarily 
applies less force. If this reduction of force is too excessive, the moving forearm may drop and 
extend due to gravity. This anomalous behavior was very rare, and the computation of key 
outcome parameters were not affected. Second, spasticity kinetic behavior with no catch were 
similar to rigidity kinetic behavior especially at slow and medium stretch speeds (Figure 3.5(c-
d)). These spasticity subjects demonstrated a uniformly elevated muscle resistance, a common 
behavioral feature of rigidity, (Figure 3.5(c-d)). Since the catch-release behavior was absent for 
most spasticity subjects at slow and medium stretch speeds, the biomechanical difference 
between spastic and rigid arm may be only recognized at sufficiently fast stretch speeds. Thus, 
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reaching large enough stretch speed was very important to differentiate spasticity from rigidity, 
since the response to high stretch speed distinguished spasticity from rigidity.  
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Figure 3.4. Example data of single trial of common kinetic and kinematic behavior during passive 
extension for various levels of (a) rigidity and (b) spasticity and control participants. For the spasticity data, 
the locations of catch (open circle), release (open triangle), and local maximum of ω after release (filled 
circle) are shown. All trials were conducted at preferred stretch speed. 
 
(a) Rigidity  
(b) Spasticity  
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Figure 3.5. Examples of irregular kinetic behavior for the rigidity and spasticity subjects. (a) Excessive 
torque (open circle) was applied at the beginning of range of motion (ROM), or the resistance continued to 
increase linearly instead of being constant across the ROM. (b) Spasticity subjects displayed excessive 
release behavior only during flexion trials. (c, d) The spastic arm without catch resembled a rigid arm. 
 
(a) (b) 
(c) (d) 
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Figure 3.6. Stretch speed dependency of applied torque (SSD) of control, spasticity, and rigidity in (a) 
extension and (b) flexion.  
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Table 3.3. Outcome parameters of control subjects during passive extension 
CONTROL (n=15) Extension 
Stretch 
Speed 
Key Outcome Parameter Non-Key Outcome Parameter 
ROM 
(˚) 
𝝎𝒂𝒗𝒈 
(˚/s) 
𝝎𝒎𝒂𝒙 
(˚/s) 
𝝉𝒂𝒗𝒈 
(Nm) 
𝝉𝒎𝒂𝒙 
(Nm) 
𝚫𝝉 (Nm) 
𝜽𝝎𝒓𝒊𝒔𝒆 
(˚) 
𝜽𝝎𝒇𝒂𝒍𝒍 
(˚) 
𝑺𝒂𝒗𝒈 
(Nm/˚) 
𝑺𝒔𝒕𝒅 
(Nm/˚) 
𝑺𝒎𝒂𝒙 
(Nm/˚) 
𝑬𝒏𝒐𝒓𝒎 
(J) 
𝑺𝑺𝑫 
(Nm*s/˚) 
?̅?* STD** ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD 
Slow 103 8 13 2 23 3 0.9 0.6 2.1 0.9 - - 16 21 84 19 1.9 0.4 2.4 0.5 7.8 3.4 1.5 1.0 - 
Med 115 7 46 8 82 20 1.0 0.6 2.3 0.9 - - 11 2 107 9 3.3 1.0 4.2 1.3 11.9 4.3 1.9 1.2 - 
Fast 119 7 82 15 154 35 1.2 0.7 3.3 0.9 - - 9 2 111 6 6.6 2.0 8.4 2.9 22.3 9.3 2.2 1.5 - 
Pref 121 7 86 11 165 34 1.0 0.5 3.1 0.7 0.1 0.5 9 2 112 7 6.7 2.1 8.5 2.6 21.7 7.2 1.8 0.9 - 
Avg 115 10 57 31 106 63 1.0 0.6 2.7 1.0 - - 11 11 104 16 4.6 2.6 5.9 3.4 16.0 9.0 1.8 1.2 0.00056 
*?̅? is the mean of parameters computed for three trials  
**STD is the standard deviation of the mean for three trials  
 
Table 3.4. Outcome parameters of control subjects during passive flexion 
CONTROL (n=15) Flexion 
Stretch 
Speed 
Key Outcome Parameter Non-Key Outcome Parameter 
ROM 
(˚) 
𝝎𝒂𝒗𝒈 
(˚/s) 
𝝎𝒎𝒂𝒙 
(˚/s) 
𝝉𝒂𝒗𝒈 
(Nm) 
𝝉𝒎𝒂𝒙 
(Nm) 
𝚫𝝉 (Nm) 
𝜽𝝎𝒓𝒊𝒔𝒆 
(˚) 
𝜽𝝎𝒇𝒂𝒍𝒍 
(˚) 
𝑺𝒂𝒗𝒈 
(Nm/˚) 
𝑺𝒔𝒕𝒅 
(Nm/˚) 
𝑺𝒎𝒂𝒙 
(Nm/˚) 
𝑬𝒏𝒐𝒓𝒎 
(J) 
𝑺𝑺𝑫 
(Nm*s/˚) 
?̅?* STD** ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD 
Slow 108 10 12 3 26 8 1.7 1.7 3.6 2.2 - - 8 12 74 28 1.7 0.5 2.3 0.7 9.4 13.3 2.8 3.0 - 
Med 104 8 50 12 76 18 0.9 1.1 2.6 1.7 - - 16 14 97 12 3.4 1.0 4.1 1.2 12.0 5.4 1.9 2.2 - 
Fast 108 9 109 26 176 49 1.1 1.3 3.2 1.6 - - 12 3 102 11 7.7 3.6 9.4 4.9 25.3 11.1 2.2 2.6 - 
Pref 108 10 119 28 188 47 0.8 1.2 2.9 1.7 −0.9 1.4 11 3 103 13 9.1 4.8 11.2 6.1 30.8 15.5 1.6 2.6 - 
Avg 107 9 72 48 117 76 1.1 1.4 3.1 1.9 - - 12 10 94 21 5.5 4.3 6.7 5.4 19.4 14.9 2.1 2.7 -0.0068 
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Table 3.5. Outcome parameters of rigidity subjects during passive extension. 
 
 
Rigidity (n=11) Extension 
Score  Stretch 
Speed 
Key Outcome Parameter Non-Key Outcome Parameter 
ROM (˚) 𝝎𝒂𝒗𝒈 
(˚/s) 
𝝎𝒎𝒂𝒙 (˚/s) 𝝉𝒂𝒗𝒈 
(Nm) 
𝝉𝒎𝒂𝒙 
(Nm) 
𝚫𝝉  
(Nm) 
𝜽𝝎_𝒓𝒊𝒔𝒆(˚) 𝜽𝝎_𝒇𝒂𝒍𝒍(˚) 𝑺𝒂𝒗𝒈 (Nm/˚) 𝑺𝒔𝒕𝒅 (Nm/˚) 𝑺𝒎𝒂𝒙 (Nm/˚) 𝑬𝒏𝒐𝒓𝒎 (J) 𝑺𝑺𝑫 
(Nm*s/˚) ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? 
UPDRS-1  
(n=3) 
S 91 4 14 3 30 7 4.0 1.3 6.2 1.5 - 
- 
- 
- 
- 
- 
5 4 72 11 2.8 0.4 3.5 0.5 10.3 1.4 6.4 2.1 - 
- 
- 
- 
- 
- 
- 
- 
M 100 7 48 12 85 25 5.4 0.9 7.7 1.7 - 
- 
- 
- 
- 
- 
11 2 91 9 5.7 1.7 6.7 1.7 19.0 5.6 10.4 1.8 - 
 
F 106 9 76 10 143 18 6.6 0.7 9.5 1.2 - 
- 
- 
- 
- 
- 
9 3 99 9 9.9 3.0 10.9 2.4 29.7 4.0 13.2 1.5 - 
 
P 106 10 79 11 148 14 6.2 1.3 9.5 2.7 2.2 1.0 8 2 98 10 9.5 1.9 10.6 2.0 32.1 9.1 11.9 2.8 
 
Avg 101 10 54 28 101 51 5.5 1.5 8.2 2.3 - - 8 3 90 14 7.0 3.5 7.9 3.5 22.8 10.5 10.5 3.3 0.035 
- 
UPDRS-2 
(n=6) 
S 87 8 12 3 25 4 5.7 1.6 9.2 3.3 - - 3 3 70 14 3.5 2.3 4.5 2.9 16.9 9.2 9.2 2.9 - 
- 
- 
- 
- 
- 
- 
- 
M 95 6 36 9 65 14 7.5 2.6 11.6 4.3 - - 9 10 86 8 6.5 1.9 7.5 2.3 24.4 9.9 14.1 5.2 - 
 
F 92 24 60 23 121 44 7.6 3.0 12.6 5.5 - - 6 2 83 24 11.3 4.8 13.3 5.5 40.2 14.6 15.7 7.0 - 
 
P 95 7 59 13 113 24 8.0 2.4 12.0 4.0 2.3 1.6 6 2 87 7 10.1 2.8 12.4 3.6 38.0 13.2 15.8 5.1 
 
Avg 92 14 42 24 81 47 7.2 2.6 11.3 4.5 - - 6 6 81 16 7.8 4.4 9.4 5.2 29.9 15.3 13.7 5.9 0.051 
- 
UPDRS-3  
(n=2) 
S 78 20 8 3 18 7 7.7 2.9 11.2 3.7 - - 16 14 76 18 2.8 0.6 3.6 0.8 13.8 6.1 12.6 5.2 - 
- 
- 
- 
- 
- 
- 
- 
M 102 4 36 3 60 7 7.3 4.9 11.0 6.7 - - 7 2 93 6 5.7 2.0 6.3 1.9 20.5 7.3 13.4 9.4 - 
 
F 106 4 71 14 125 16 10.3 4.2 15.1 6.0 - - 9 3 96 6 13.0 1.9 14.8 2.5 46.9 9.9 20.3 9.8 - 
 
P 105 7 62 16 117 34 10.3 5.5 16.2 9.1 2.6 2.3 8 2 93 5 11.9 3.3 13.2 2.9 41.1 9.4 18.7 11.8 
 
Avg 98 16 44 27 80 48 8.9 4.7 13.4 7.0 - - 10 8 89 13 8.3 4.8 9.5 5.1 30.6 16.1 16.3 9.9 0.050 
- 
Total  
(n=11) 
S 86 11 12 3 25 7 5.6 2.2 8.8 3.4 - - 6 8 72 15 3.2 1.8 4.0 2.2 14.5 7.9 9.1 3.9 - 
- 
- 
- 
- 
- 
- 
- 
M 97 7 39 11 69 20 6.9 3.0 10.4 4.7 - - 9 8 88 8 6.1 1.9 7.1 2.1 22.2 8.8 13.0 5.9 - 
 
F 98 20 67 20 128 36 7.8 3.2 12.2 5.2 - - 7 3 90 20 11.2 4.1 12.9 4.6 38.5 13.2 15.9 7.1 - 
 
P 100 10 65 16 123 29 7.9 3.3 12.1 5.6 2.3 1.6 7 2 91 9 10.3 2.8 12.0 3.3 37.0 12.0 15.3 6.9 
 
Avg 95 14 46 26 86 49 7.1 3.1 10.9 5.0 - - 8 6 85 16 7.7 4.3 9.0 4.8 28.1 14.7 13.3 6.6 0.045 
- 
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Table 3.6. Outcome parameters of rigidity subjects during passive flexion 
 
  
Rigidity (n=11) Flexion 
Score 
Stretc
h 
Speed 
Key Outcome Parameter Non-Key Outcome Parameter 
ROM (˚) 𝝎𝒂𝒗𝒈 
(˚/s) 
𝝎𝒎𝒂𝒙 (˚/s) 𝝉𝒂𝒗𝒈 
(Nm) 
𝝉𝒎𝒂𝒙 
(Nm) 
𝚫𝝉 
(Nm) 
𝜽𝝎_𝒓𝒊𝒔𝒆(˚) 𝜽𝝎_𝒇𝒂𝒍𝒍(˚) 𝑺𝒂𝒗𝒈 (Nm/˚) 𝑺𝒔𝒕𝒅 (Nm/˚) 𝑺𝒎𝒂𝒙 (Nm/˚) 𝑬𝒏𝒐𝒓𝒎 (J) 𝑺𝑺𝑫 
(Nm*s/˚) ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? ST
D 
?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? 
UPDRS-1 
(n=3) 
S 104 7 11 2 27 9 3.2 1.7 5.5 2.1 - 
- 
- 
- 
- 
- 
15 21 89 12 2.6 0.4 3.3 0.5 11.1 3.1 5.7 2.7 - 
- 
- 
- 
- 
- 
- 
- 
M 104 6 48 9 86 23 3.9 1.7 6.4 2.4 - 
- 
- 
- 
- 
- 
13 9 97 12 4.9 1.0 5.7 1.5 17.1 3.8 7.8 3.5 - 
 
F 110 9 81 18 144 37 5.1 1.3 9.3 2.5 - 
- 
- 
- 
- 
- 
7 5 101 17 9.6 4.2 10.6 5.7 29.7 12.6 10.8 2.7 - 
 
P 105 9 75 20 136 42 2.9 1.0 6.5 2.1 -0.3 1.5 8 6 96 15 8.6 3.2 9.5 4.4 25.1 8.6 6.4 3.7 
 
Avg 106 8 54 31 98 56 3.8 1.7 6.9 2.7 - - 11 13 96 15 6.4 3.9 7.3 4.7 20.8 10.8 7.7 3.7 0.0028 
- 
UPDRS-2 
(n=6) 
S 103 14 11 3 24 6 8.2 4.1 12.6 5.8 - - 9 10 82 23 3.4 1.1 4.3 1.4 15.8 6.8 14.0 7.1 - 
- 
- 
- 
- 
- 
- 
- 
M 99 13 54 15 83 21 7.3 2.8 12.1 4.4 - - 9 4 93 16 7.8 2.8 7.5 2.9 24.2 9.8 14.2 5.7 - 
 
F 102 14 101 23 160 29 7.2 3.3 13.3 5.1 - - 10 5 100 14 15.0 5.8 14.1 7.5 41.4 16.8 15.7 7.7 - 
 
P 100 13 78 19 126 39 7.1 4.1 11.7 6.2 -1.1 0.9 9 4 92 20 12.9 8.5 14.1 11.2 39.9 31.2 15.1 9.8 
 
Avg 101 14 61 37 98 58 7.4 3.7 12.4 5.5 - - 10 6 92 20 9.7 7.0 10.0 8.1 30.3 21.6 14.8 7.8 -0.012 
- 
UPDRS-3 
(n=2) 
S 105 5 9 1 24 10 13.2 7.0 18.4 8.4 - - 10 12 88 15 3.9 1.9 4.9 2.4 16.6 8.4 21.6 11.0 - 
- 
- 
- 
- 
- 
- 
- 
M 93 8 34 4 62 8 9.2 6.1 15.9 10.7 - - 8 3 85 6 7.0 3.8 6.2 2.5 18.7 8.5 18.1 12.0 - 
 
F 105 12 97 21 158 22 8.6 6.4 16.8 12.2 - - 12 7 103 11 15.1 6.6 13.2 3.8 44.7 14.8 20.1 15.7 - 
 
P 103 3 94 19 156 24 7.6 5.6 14.4 9.9 -5.6 2.1 13 5 95 12 13.8 5.8 11.0 2.8 37.2 9.4 17.3 13.2 
 
Avg 101 9 59 41 100 61 9.7 6.7 16.4 10.5 - - 11 8 93 13 10.0 6.7 8.8 4.5 29.3 16.0 19.3 13.2 -0.016 
Total 
(n=11) 
S 103 11 11 3 25 8 7.8 5.5 11.7 7.2 - - 11 15 85 20 3.2 1.3 4.1 1.6 14.7 6.8 13.1 8.9 - 
- 
- 
- 
- 
- 
- 
- 
M 100 12 49 14 80 22 6.7 3.9 11.2 6.6 - - 10 6 93 14 6.9 2.9 6.8 2.7 21.3 8.9 13.2 7.7 - 
 
F 105 13 95 23 155 31 6.9 3.9 12.8 7.0 - - 10 6 101 15 13.5 6.1 13.0 6.7 38.8 16.4 15.2 9.4 - 
 
P 102 11 80 20 134 39 6.0 4.4 10.8 6.9 -1.8 1.5 10 5 94 17 11.9 7.2 12.3 8.9 35.4 24.7 13.1 10.3 
 
Avg 102 12 59 37 98 58 6.8 4.5 11.6 7.0 - - 10 9 93 18 8.9 6.4 9.0 6.9 27.5 18.7 13.6 9.2 -0.0084 
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Table 3.7. Outcome parameters of spasticity subjects during passive extension.  
a,b,c Only three subjects (MAS 3,4, n=1,2) could perform fast stretch velocities 
 
Spasticity (n=15) Extension 
Score Stretch 
Speed 
Key Outcome Parameter Non-Key Outcome Parameter 
ROM (˚) 𝝎𝒂𝒗𝒈 
(˚/s) 
𝝎𝒎𝒂𝒙 (˚/s) 𝝉𝒂𝒗𝒈 
(Nm) 
𝝉𝒎𝒂𝒙 
(Nm) 
𝚫𝝉 
(Nm) 
𝜽𝝎_𝒎𝒂𝒙(˚) 𝑺𝒂𝒗𝒈 (Nm/˚) 𝑺𝒔𝒕𝒅 (Nm/˚) 𝑺𝒎𝒂𝒙 (Nm/˚) 𝑬𝒏𝒐𝒓𝒎 (J) 𝑺𝑺𝑫 
(Nm*s/˚) 
Catch 
(%) ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? STD ?̅? ?̅? 
MAS-1 (n=3) 
S 84 11 11 2 24 4 1.5 0.8 2.9 0.8 - 
- 
- 
- 
- 
- 
33 26 1.8 0.3 2.3 0.4 6.8 1.4 2.4 1.4 - 
- 
- 
- 
- 
- 
- 
- 
0.0 
M 92 21 57 13 113 25 3.4 2.1 5.7 2.7 - 
- 
- 
- 
- 
- 
39 8 6.1 4.0 6.8 4.4 18.7 11.3 5.8 4.0 - 
 
0.0 
F 94 13 100 25 303 52 6.6 2.6 11.4 4.8 - 
- 
- 
- 
- 
- 
43 6 19.4 8.9 27.6 14.8 78.8 43.0 12.4 6.8 - 
 
22.2 
P 101 13 111 25 311 40 6.4 2.0 11.1 3.6 4.9 1.4 47 7 19.5 8.2 23.3 10.8 60.9 23.6 11.2 4.6 - 
 
22.2 
Avg 93 16 70 43 188 128 4.5 2.9 7.8 4.9 - - 41 15 11.7 10.1 15.0 14.3 41.3 38.8 7.9 6.2 0.047 10.3 
MAS-2 (n=4) 
S 89 11 11 2 23 9 2.6 0.8 4.3 1.3 - - 32 17 2.0 0.8 2.5 0.9 7.3 2.3 4.0 1.3 - 
- 
- 
- 
- 
- 
- 
- 
0.0 
M 96 15 35 10 96 26 5.1 1.0 6.9 1.5 - - 30 17 4.8 1.1 6.5 1.5 22.7 8.8 8.9 1.7 - 
 
33.3 
F 108 15 76 12 203 52 6.4 1.2 11.2 1.8 - - 41 16 14.9 3.4 20.5 5.6 62.1 18.7 12.0 1.8 - 
 
75.0 
P 104 17 74 25 200 41 6.7 1.7 10.3 2.2 4.1 1.3 45 16 12.9 3.2 17.5 3.6 52.1 7.8 12.7 3.2 - 
 
33.3 
Avg 98 16 45 30 120 83 5.0 2.0 7.8 3.2 - - 36 18 7.9 5.8 10.7 8.1 33.0 24.3 9.0 4.0 0.11 
- 
34.6 
MAS-3 (n=4) 
S 60 12 8 2 20 8 3.2 1.0 5.1 1.1 - - 17 12 2.2 0.5 2.7 0.6 9.6 2.4 4.9 1.6 - 
- 
- 
- 
- 
- 
- 
- 
0.0 
M 67 10 37 8 137 69 6.7 2.2 12.8 6.8 - - 28 9 15.5 14.1 26.5 31.2 98.9 127.5 9.9 3.6 - 
 
50.0 
Fa (n=1) 90 2 66 4 208 20 12.1 0.3 16.5 0.2 - - 34 2 17.4 2.3 24.4 3.2 85.1 7.9 20.4 1.8 
 
16.7 
P 69 11 45 12 193 47 6.5 2.3 14.5 5.5 3.3 1.7 29 8 21.7 13.1 38.2 27.6 133.1 105.9 10.7 4.6 - 
 
91.7 
Avg 67 13 33 20 124 87 6.0 3.0 11.3 6.5 - - 26 11 13.4 13.3 22.6 27.1 80.9 104.7 9.4 5.3 0.13 44.2 
MAS-4 (n=4) 
S 75 8 10 2 23 10 2.9 0.8 5.2 1.2 - - 20 12 2.2 0.6 2.7 0.8 9.4 3.6 4.1 1.3 - 
- 
- 
- 
- 
- 
- 
- 
 
 
 
 
 
0.0 
M 76 12 34 10 142 30 8.1 3.3 12.2 4.5 - - 30 6 9.8 4.8 13.5 5.0 44.1 11.8 12.2 4.8 - 
 
66.7 
Fb (n=2) 83 2 38 17 167 57 10.4 4.9 15.0 8.0 - - 26 12 15.9 12.0 22.6 16.0 79.6 53.4 14.0 5.9 
 
50.0 
P 78 9 42 20 172 28 9.7 5.1 14.2 7.3 6.8 3.0 31 9 14.3 9.5 20.2 10.7 74.4 29.2 14.4 7.0 - 
 
75.0 
Avg 77 9 30 19 120 70 7.4 4.8 11.2 6.8 - - 27 11 9.8 9.0 13.6 11.6 47.9 38.3 10.8 6.7 0.20 50.0 
Total  
(n=15) 
S 77 15 10 3 22 8 2.6 1.1 4.5 1.4 - - 25 18 2.1 0.6 2.6 0.7 8.3 2.9 3.9 1.7 - 
- 
- 
- 
- 
- 
- 
- 
0.0 
M 82 19 40 13 123 47 6.0 2.9 9.7 5.4 - - 31 12 9.2 9.0 13.8 18.4 47.9 73.9 9.4 4.3 - 
 
40.0 
Fc (n=12) 96 15 74 29 229 74 8.0 3.6 12.7 5.2 - - 38 13 16.9 8.1 23.8 12.3 74.1 38.1 13.5 5.6 
 
42.2 
P 86 19 64 34 214 65 7.4 3.6 12.8 5.6 4.8 2.4 37 13 17.2 10.2 25.4 18.6 83.5 68.0 12.3 5.4 - 
 
57.8 
Avg 84 19 44 33 136 97 5.8 3.5 9.5 5.8 - - 32 15 10.6 10.1 15.4 17.3 50.6 62.5 9.3 5.7 0.12 36.4 
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Table 3.8. Catch-release parameters of spasticity subjects during passive extension.  
Spasticity (n=15) Extension 
Score 
Stretch 
Speed 
Catch-release Behavior 
𝜽𝒄𝒂𝒕𝒄𝒉 (˚) 𝜶𝒄𝒂𝒕𝒄𝒉(˚/s2) 𝝉𝒄𝒂𝒕𝒄𝒉(Nm) 𝜽𝒓𝒆𝒍𝒆𝒂𝒔𝒆 (˚) 𝜶𝒓𝒆𝒍𝒆𝒂𝒔𝒆(˚/s2) 𝝉𝒓𝒆𝒍𝒆𝒂𝒔𝒆(Nm) 𝝉𝒑𝒐𝒔𝒕−𝒓𝒆𝒍𝒆𝒂𝒔𝒆(Nm) 𝑬𝒑𝒐𝒔𝒕−𝒓𝒆𝒍𝒆𝒂𝒔𝒆(𝑱) 
𝒙 STD 𝒙 STD 𝒙 STD 𝒙 STD 𝒙 STD 𝒙 STD 𝒙 STD 𝒙 STD 
MAS-1 (n=3) 
S - - - - - - - - - - - - - - - - 
M - - - - - - - - - - - - - - - - 
F 69 20 -1804 662 13.3 0.6 99 15 -689 23 8.3 0.7 7.8 0.7 8.1 2.1 
P 84 7 -1614 438 8.8 4.2 101 13 -296 71 4.9 1.1 6.6 1.4 3.5 1.7 
Avg 77 17 -1709 569 11.0 3.7 100 14 -492 203 6.6 1.9 7.2 1.2 5.8 3.0 
MAS-2 (n=4) 
S - - - - - - - - - - - - - - - - 
M 36 23 -611 277 6.4 1.9 42 22 186 186 4.7 2.1 5.9 0.9 5.4 1.1 
F 54 20 -899 384 11.2 1.8 70 22 88 309 7.6 2.0 7.8 1.7 7.1 1.2 
P 54 18 -825 341 11.0 1.7 70 21 -90 226 8.3 1.6 8.3 1.1 7.0 1.4 
Avg 50 22 -814 370 10.0 2.7 63 25 69 283 7.1 2.4 7.5 1.6 6.7 1.4 
MAS-3 (n=4) 
S - - - - - - - - - - - - - - - - 
M 46 13 -1278 925 15.8 7.9 52 11 164 264 5.4 3.7 8.7 3.2 3.6 1.7 
Fa (n=1) 50 1 -727 175 15.2 1.3 63 4 -425 31 13.5 0.4 15.1 0.1 10.0 0.0 
P 46 11 -1275 627 14.6 5.8 54 10 190 186 5.3 3.0 7.4 3.1 3.4 1.9 
Avg 46 11 -1218 728 15.0 6.3 54 11 117 277 6.2 4.0 8.6 3.7 4.2 2.6 
MAS-4 (n=4) 
S - - - - - - - - - - - - - - - - 
M 45 9 -846 211 9.4 3.5 53 9 62 137 7.2 2.6 8.0 4.4 4.6 2.6 
Fb (n=2) 42 20 -1004 580 13.1 7.9 49 20 154 179 9.5 6.7 12.4 6.7 6.6 2.2 
P 48 13 -997 211 12.2 6.5 56 15 47 222 9.7 5.8 10.9 7.4 6.0 3.6 
Avg 45 15 -946 355 11.5 6.2 53 15 80 190 8.8 5.3 10.3 6.5 5.7 3.0 
Total  
(n=15) 
S - - - - - - - - - - - - - - - - 
M 43 15 -938 623 10.9 6.3 50 14 124 206 6.0 3.1 7.8 3.7 4.4 2.1 
Fc (n=12) 51 21 -1010 553 12.4 4.8 65 24 -27 367 8.9 4.4 10.0 4.8 7.3 1.9 
P 51 16 -1136 512 12.8 5.8 60 19 60 246 7.3 4.5 8.7 5.1 4.9 2.9 
Avg 49 18 -1041 564 12.1 5.7 59 21 52 285 7.4 4.3 8.8 4.7 5.5 2.7 
a,b,c Only some severely spastic subjects (MAS 3 (n=1), MAS 4 (n=2)) could perform fast stretch velocities 
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Table 3.9. Outcome parameters of spasticity subjecting during passive flexion.  
a,b,c Only a few severe spasticity subjects (MAS 3 (n=4), MAS 4 (n=0)) could perform fast stretch velocities.  
d MAS 4 subjects had severe arm contractions and abnormal resting arm postures that reduced the range of motion during flexion. 
 
Spasticity (n=15) Flexion 
Score Stretch 
Speed 
Key Outcome Parameter Non-Key Outcome Parameter 
ROM (˚) 𝝎𝒂𝒗𝒈 
(˚/s) 
𝝎𝒎𝒂𝒙 
(˚/s) 
𝝉𝒂𝒗𝒈 
(Nm) 
𝝉𝒎𝒂𝒙 
(Nm) 
𝚫𝝉 
(Nm) 
𝜽𝝎_𝒎𝒂𝒙(˚) 𝑺𝒂𝒗𝒈 
(Nm/˚) 
𝑺𝒔𝒕𝒅 
(Nm/˚) 
𝑺𝒎𝒂𝒙 
(Nm/˚) 
𝑬𝒏𝒐𝒓𝒎 
(J) 
𝑺𝑺𝑫 
(Nm*s/˚
) 
Catc
h 
(%) 
𝒙 ST
D 
𝒙 ST
D 
𝒙 STD 𝒙 ST
D 
𝒙 ST
D 
𝒙 ST
D 
𝒙 STD 𝒙 STD 𝒙 STD 𝒙 STD 𝒙 STD 𝒙 𝒙 
MAS-1 
(n=3) 
S 10
0 
5 11 1 22 2 2.7 1.2 4.5 1.2 - 
- 
- 
- 
- 
- 
38 22 2.1 0.7 2.7 0.9 9.9 3.6 4.6 2.2 - 
- 
- 
- 
- 
- 
- 
- 
0.0 
M 91 6 59 15 86 18 2.5 0.8 4.0 0.9 - 
- 
- 
- 
- 
- 
60 21 4.5 1.6 5.5 2.3 17.4 7.0 4.8 1.6 - 
 
0.0 
F 10
2 
8 16
6 
85 288 129 3.4 1.5 7.4 2.7 
- - 
52 13 22.6 9.4 25.7 8.5 56.3 18.0 6.9 3.5 
 
11.1 
P 98 9 17
2 
70 298 104 2.9 1.0 7.5 2.3 0.
2 
1.1 51 13 22.8 5.6 24.2 6.6 56.5 19.9 6.1 2.3 - 
 
22.2 
Avg 98 8 10
2 
89 173 148 2.9 1.2 5.9 2.5 - - 50 19 13.0 11.2 14.5 11.8 35.0 25.7 5.6 2.7 -0.0022 10.3 
MAS-2 
(n=3) 
S 10
7 
14 13 2 26 4 4.6 3.7 7.2 5.7 - - 34 18 2.1 0.8 2.5 0.8 8.0 2.4 7.4 5.9 - 
- 
- 
- 
- 
- 
- 
- 
0.0 
M 10
4 
13 72 23 117 48 4.2 2.0 7.1 3.5 - - 65 25 6.5 2.8 6.6 2.8 20.6 8.3 8.1 4.4 - 
 
0.0 
F 10
7 
12 15
5 
34 252 35 5.8 2.1 12.
1 
3.4 - - 51 10 20.2 2.8 18.6 3.8 50.6 8.6 12.
3 
4.8 
 
11.1 
P 11
1 
8 14
5 
21 295 43 6.6 2.0 11.
8 
2.9 2.
0 
2.8 46 8 22.8 3.4 25.0 5.4 58.3 16.3 13.
1 
5.2 - 
 
33.3 
Avg 10
7 
12 96 62 172 113 5.3 2.7 9.6 4.7 - - 49 20 12.9 9.2 13.2 9.7 34.4 23.1 10.
2 
5.7 0.010 
- 
12.8 
MAS-3 
(n=5) 
S 87 10 11 3 23 6 8.6 3.4 12.
8 
4.8 - - 23 15 2.9 0.8 3.4 0.9 12.9 3.4 13.
7 
4.9 - 
- 
- 
- 
- 
- 
- 
- 
0.0 
M 88 10 55 9 112 12 9.9 3.2 16.
5 
5.6 - - 39 10 13.1 4.9 12.4 4.4 39.9 16.2 20.
0 
6.3 - 
 
0.0 
Fa (n=4) 94 9 62 16 236 25 15.
7 
4.5 26.
5 
7.2 - - 37 8 28.0 11.6 40.4 17.6 124.8 58.1 30.
8 
8.9 
 
60.0 
P 87 7 67 21 215 29 13.
9 
6.7 23.
3 
9.5 5.
3 
3.1 40 10 26.0 13.4 32.4 17.0 96.3 44.7 27.
0 
12.
4 
- 
 
66.7 
Avg 89 10 48 27 142 88 11.
8 
5.5 19.
4 
8.8 - - 35 13 16.9 13.6 21.2 19.0 65.5 56.6 22.
4 
10.
8 
0.081 35.4 
MAS-4 
(n=4) 
S 72 14 8 2 22 8 8.1 3.3 10.
8 
3.6 - - 15 6 3.0 0.7 3.7 0.8 12.4 2.0 13.
4 
5.5 - 
- 
- 
- 
- 
- 
- 
- 
0.0 
M 71 11 49 19 107 24 8.3 4.1 13.
5 
4.8 - - 40 22 12.3 3.7 15.3 5.7 56.2 25.6 16.
8 
6.8 - 
 
0.0 
Fb (n=0) - - - - - - - - - - - - - - - - - - - - - - - - 
P 65 11 64 31 149 25 7.9 4.7 14.
5 
8.1 -
0.
2 
2.8 34 14 16.7 4.7 20.3 8.6 69.0 32.7 16.
6 
8.5 - 
 
33.3 
Avg 69 12 40 32 92 57 8.1 4.1 12.
9 
6.0 - - 30 19 10.7 6.7 13.1 9.2 45.9 34.1 15.
6 
7.2 0.17 10.3 
Total  
(n=15) 
S 91 17 11 3 23 6 6.4 4.0 9.4 5.4 - - 27 18 2.6 0.9 3.2 1.0 11.1 3.6 10.
3 
6.2 - 
- 
- 
- 
- 
- 
- 
- 
0.0 
M 88 15 58 18 106 29 6.7 4.2 11.
2 
6.7 - - 49 22 9.7 5.2 10.3 5.6 34.4 21.8 13.
5 
8.3 - 
 
0.0 
Fc 
(n=10) 
10
1 
11 12
1 
70 256 78 9.1 6.4 16.
5 
9.9 - - 46 12 24.0 9.7 29.4 15.4 82.0 52.0 18.
1 
12.
5  
26.2 
P 90 18 10
6 
61 236 81 8.7 6.3 15.
6 
9.4 1.
8 
2.4 42 13 22.6 9.5 26.4 12.5 73.8 37.2 17.
3 
11.
9 
- 
 
42.9 
Avg 92 16 70 62 148 110 7.6 5.4 12.
9 
8.4 - - 32 15 14.0 11.4 16.4 14.6 47.9 42.9 14.
5 
10.
3 
0.065 19.8 
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Table 3.10. Catch-release parameters of spasticity subjects during passive flexion.  
Spasticity (n=15) Flexion 
Score 
Stretc
h 
Speed 
Catch-release Behavior 
𝜽𝒄𝒂𝒕𝒄𝒉 (˚) 𝜶𝒄𝒂𝒕𝒄𝒉(˚/s2) 𝝉𝒄𝒂𝒕𝒄𝒉(Nm) 𝜽𝒓𝒆𝒍𝒆𝒂𝒔𝒆 (˚) 𝜶𝒓𝒆𝒍𝒆𝒂𝒔𝒆(˚/s2) 𝝉𝒓𝒆𝒍𝒆𝒂𝒔𝒆(Nm) 𝝉𝒑𝒐𝒔𝒕−𝒓𝒆𝒍𝒆𝒂𝒔𝒆(Nm) 𝑬𝒑𝒐𝒔𝒕−𝒓𝒆𝒍𝒆𝒂𝒔𝒆(𝑱) 
𝒙 STD 𝒙 STD 𝒙 STD 𝒙 STD 𝒙 STD 𝒙 STD 𝒙 STD 𝒙 STD 
MAS-1  
(n=3) 
S - - - - - - - - - - - - - - - - 
M - - - - - - - - - - - - - - - - 
F 71 0 -1811 0 8.0 0.0 88 0 329 0 3.3 0.0 4.7 0.0 2.2 0.0 
P 77 2 -2190 222 8.4 1.0 92 3 675 214 1.7 0.0 4.1 0.5 1.9 0.4 
Avg 75 3 -2063 255 8.3 0.8 91 3 559 239 2.2 0.8 4.3 0.5 2.0 0.3 
MAS-2  
(n=3) 
S - - - - - - - - - - - - - - - - 
M - - - - - - - - - - - - - - - - 
F 51 0 -331 0 9.4 0.0 110 0 -454 0 4.4 0.0 6.2 0.0 7.6 0.0 
P 59 22 -810 326 10.0 1.5 93 19 77 475 5.5 0.9 7.3 0.9 6.5 2.0 
Avg 57 19 -690 350 9.8 1.4 97 18 -55 471 5.2 0.9 7.0 0.9 6.8 1.8 
MAS-3 
 (n=5) 
S - - - - - - - - - - - - - - - - 
M - - - - - - - - - - - - - - - - 
Fa 
(n=4) 63 6 -1266 419 28.5 6.7 75 8 126 186 18.9 6.5 20.8 6.8 10.6 3.5 
P 61 6 -1184 432 28.8 6.0 69 5 80 237 23.3 5.6 24.4 6.2 10.3 3.4 
Avg 62 6 -1223 428 28.7 6.3 72 7 102 216 21.2 6.4 22.7 6.7 10.4 3.5 
MAS-4 d 
(n=4) 
S - - - - - - - - - - - - - - - - 
M - - - - - - - - - - - - - - - - 
Fb 
(n=0) - - - - - - - - - - - - - - - - 
P 34 3 -485 113 25.3 1.9 38 4 -106 111 19.0 3.5 15.6 1.7 6.1 2.9 
Avg 34 3 -485 113 25.3 1.9 38 4 -106 111 19.0 3.5 15.6 1.7 6.1 2.9 
Total 
 (n=15) 
S - - - - - - - - - - - - - - - - 
M - - - - - - - - - - - - - - - - 
Fc 
(n=10) 63 7 -1231 499 24.9 9.8 79 13 92 248 16.2 8.3 18.0 8.6 9.6 4.0 
P 58 16 -1117 585 22.8 9.6 71 20 115 346 17.2 9.5 17.8 9.3 8.0 4.1 
Avg 60 13 -1160 556 23.6 9.7 74 18 106 313 16.8 9.1 17.9 9.0 8.6 4.1 
a,b,c Only a few severe spasticity subjects (MAS 3 (n=4), MAS 4 (n=0)) were able to perform fast stretch velocities. d MAS 4 subjects 
had severe arm contractions and abnormal resting arm postures that reduced the range of motion during flexion.
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3.4.3 LIMITATIONS 
A limitation of this study was the sole reliance on measuring mechanical responses for 
investigating spasticity and rigidity. Some argued that these mechanical responses can be less 
sensitive to changes in motoneuronal excitability and more influenced by factors other than 
spasticity and rigidity, for example, the rheological changes in muscle properties [28]. Thus, one 
can argue that measurement of motoneuronal activity such as recordings of electromyographic 
(EMG) signal is more important than measuring biomechanical responses for accurately 
understanding the pathophysiology of spasticity and rigidity. While the surface EMG electrodes 
of the PVRM did not have high enough resolution of muscle activity data to be used for 
investigation of motoneuronal activity, the use of EMG may not be practical in a clinical setting 
or even necessary. Incorporation of EMG in a clinical setting can be impractical if not impossible 
due to the requirements demanded by a clinical setting, that is relatively inexpensive, time-
efficient, and simple method for assessing abnormal muscle conditions. For accurate and reliable 
EMG readings, it is critical to prepare the skin thoroughly to remove dead skin cells to optimize 
conductivity of the [134–136]. In addition, the surface EMG sensors may not be needed since the 
clinicians can usually monitor the muscle activation status of the patient from haptic feedback.  
 
3.4.4 TRAINING SIMULATOR DESIGN GUIDELINES 
To mimic spasticity and rigidity for medical training purposes, two types of simulators 
have been developed: 1) an electromechanical simulator that exerts resistive torque from a motor 
programmed using a closed loop torque control and an angular position sensor feedback 
[17,58,62], or 2) a mechanical simulator that utilizes a hydraulic damper system to mimic 
velocity dependent resistance [59,61]. Both types of simulators allowed for adjustments of 
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different levels of hypertonicity to replicate different muscle behaviors of different severities of 
hypertonicity (e.g. a mechanical simulator with adjustable setting that replicates MAS 1-4 
muscle response) [59,61].  
While a mechanical simulator has advantages over an electromechanical simulator, such 
as requiring no power supply, an electromechanical simulator can be a more promising choice 
for reproducing different types of hypertonicity. Spasticity and rigidity have very different 
muscle behavior in terms of stretch velocity dependency and catch presence. This may cause 
numerous design complications for mechanical simulators, since the mechanical designs that 
mimic one type of hypertonicity (e.g., spasticity) may contradict other designs that replicate 
other types of hypertonicity (e.g., rigidity). For example, a robust simulator needs to not only 
recreate increased muscle resistance with catch-release behavior for spasticity, but also be able to 
replicate uniformly increased muscle tone without catch-release behavior for rigidity. In 
addition, the triggering of catch-release behavior needs to be stretch speed dependent and occur 
intermittently, adding more design complexities. Finally, the reactive torque from the simulator 
needs to be continuous and smooth for healthy muscle and mild spasticity, requiring tighter 
tolerances for manufacturing. All these challenges can increase the developmental and 
manufacturing time and costs. However, an electromechanical simulator can allow for high 
adjustability of joint kinematic and kinetic behaviors for all levels of rigidity, spasticity, and even 
other types of hypertonicities such as dystonia with less complications. The occasional presence 
of catch can be programmed into the controller of an electromechanical simulator by 
randomizing the occurrence of catch. Higher MAS level can increase the probability of catch 
occurrence, since severe spasticity subjects displayed more frequent catch-release behavior 
(Tables 3.7, 3.9). A mechanical simulator can be used to replicate one specific type of 
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hypertonicity, but an electromechanical simulator may be needed to recreate multiple types of 
hypertonicity.  
 
 
3.4.5 POTENTIAL AND FUTURE WORK FOR CLINICAL APPLICATION 
The PVRM can be potentially used as a clinical screening tool for evaluating 
hypertonicity. The key outcome parameters introduced in this study can assist in distinguishing 
spastic, rigid, and healthy muscles from the PVRM data. Spasticity and rigidity could be 
differentiated from healthy muscles using parameters related to muscle tone. Range of motion 
may also differentiate severe spasticity patients, as severely spastic patients demonstrated 
reduction of range of motion due to permanent contractures (Tables 3.5,3.6,3.7,3.9). To 
distinguish spasticity from rigidity, one may detect for presence of catch-release behavior. If 
catch is not present, the stretch speed dependency of muscle tone (SSD) can evaluated, since 
muscle tone from spasticity was more sensitive to stretch velocity than hypertonia from rigidity 
(Figure 3.6, Tables 3.5,3.6,3.7,3.9). Through future studies with more comprehensive subject 
demographics, it may be even possible to distinguish different levels of spasticity and rigidity 
using SSD and muscle tone related parameters, since these metrics and the MAS/UPDRS scores 
displayed an ordinal relationship.  
Some of the key outcome parameters can differentiate not only the type but also the 
severity of the hypertonicity. For example, parameters relating to muscle tone 
(𝜏𝑎𝑣𝑔, 𝜏𝑚𝑎𝑥, 𝑆𝑎𝑣𝑔, 𝑆𝑚𝑎𝑥, 𝑆𝑠𝑡𝑑 , 𝐸𝑛𝑜𝑟𝑚) can distinguish spastic and rigid muscles from healthy 
muscles, and parameters describing the stretch speed dependency of tone (i.e., SSD) can separate 
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spasticity from rigidity. In addition, the magnitudes of these parameters can classify different 
levels of hypertonicity. For example, MAS scores are proportional to SSD, and UDPRS scores 
are proportional to parameters relating to muscle tone. Classifying the type and severity of 
hypertonicity can be beneficial to clinicians and patients for identifying and monitoring the 
progression of the underlying neurological disorder. Although qualitative scales such as the 
Modified Ashworth Scale (MAS) are used currently for this purpose, inexperienced clinicians 
have difficulty reliably assessing hypertonicity using these scales due to the heavy reliance on 
the rater’s personal experience and interpretation of the scales. Therefore, the key outcome 
parameters presented in this study can potentially help the medical community by providing a 
new quantitative scale established from the PVRM data collected in future studies. Also, the 
PVRM can be optimized to automatically output a MAS or UPDRS score after a clinical 
assessment, alleviating clinicians from the burden of relying on past training experiences and 
subjective interpretation of the qualitative scales.   
With further development and additional studies, the PVRM can be optimized to 
automatically output a MAS or UPDRS score after a clinical assessment, alleviating clinicians 
from the burden of purely relying on past training experiences and subjective interpretation of 
the qualitative scales. To deploy the PVRM in a clinical environment, the PVRM hardware needs 
to be optimized for better ergonomics and reduce setup time. The current version of the PVRM 
uses a uniaxial load cell that cannot monitor unwanted torque from tilting or twisting motion, so 
the clinician needs to apply the load as perpendicular to the moving module as possible. Hence, 
the usability of the PVRM can be improved by replacing the uniaxial load cell with a 6-axis load 
cell sensor that can decouple any unwanted torque applied, allowing the clinician to freely apply 
the load to the moving module. Alternatively, it may be possible to create a wearable device that 
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the clinician can done to quantify the applied load, similar to the prototype glove developed by 
Garudadri et al. [137].  Also, the two PVRM modules and the three surface electromyographic 
(sEMG) electrodes can be simplified to a single moving module to improve the setup time. 
While the sEMG electrodes provide information regarding muscle activation status, the EMG 
electrodes may be omitted in the future versions of the PVRM due to the long setup time such as 
skin preparation and the calibration process to establish activation thresholds. Clinicians can 
typically sense voluntary muscle activation during the clinical assessments. The contents of the 
main module can be moved to the moving module, reducing the overall size and setup time of 
the PVRM even further. Knowing the relative joint angle from a single inertial measurement unit 
(IMU) could be enough to assess other key outcome parameters. In addition, the PVRM cover 
plate design needs revision to allow for the same arm position during flexion and extension 
assessments. In our study, the arm position during flexion was perpendicular to the ground, while 
the arm position during extension was parallel to the ground. For practical clinical use and more 
direct comparison of data, flexion and extension should involve a similar movement plane 
relative to the ground so that the PVRM can capture data from sequential flexion and extension 
cycles. Finally, the PVRM design should be revised to allow assessments of hypertonicity about 
multiple joints in the body such as the wrist, shoulder, hip, knee, and ankle. In particular, PVRM 
should accommodate assessments for knee and ankles, the two most common joints affected by 
spasticity, since assessments of these joints have been reported to have the lowest inter-rater 
reliability [53]. 
 Future studies with more test subjects and raters can be proposed. Additional subjects 
must be recruited to comprehensively represent the spasticity and rigidity population to perform 
statistical analysis to quantify inter-group and intra-group differences. More subjects should be 
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recruited for each MAS and UPDRS level. In addition, more raters with varying level of relevant 
clinical experience should be involved to investigate the feasibility of PVRM usage in a clinical 
and even residential setting to determine if the PVRM can reproduce repeatable results 
regardless of the rater’s experience. Ultimately, a new clinical scale can be introduced that is 
based on quantitative data rather than clinical observations. The currently used clinical scales 
such as MAS and UPDRS were based on qualitative observations from clinicians that may not 
fully represent all levels of spasticity and rigidity patient population. Thus, a quantitative scale 
established from the data such as that collected by the PVRM may allow for an automated 
classification of different levels of spasticity and rigidity.  
The testing protocol of the PVRM also needs revision in the future studies. First, the 
MAS score should be reported for every trial since a few of the MAS subject’s score changed 
during every test trial. These score changes could be attributed to not only the loosening of 
muscles due to frequent passive movements, but also other factors such as the stress level of the 
subject and inherently fluctuating nature of hypertonicity [1,3]. Second, the arm posture during 
flexion test trials should be similar during extension test trials. In our study, the arm position 
during flexion was approximately perpendicular to the ground, while the arm position during 
extension was almost parallel to the ground. For practical clinical use and more direct 
comparison of data, flexion and extension should involve a similar movement plane relative to 
the ground. Third, stretch speed for each test trial should be randomized instead of being 
sequential. Since hypertonia arising from spasticity and rigidity may change after numerous 
stretches of the muscle, the torque data collected near the end of test trials (i.e. fast and preferred 
stretch speeds) may be downscaled in our study.  
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3.5 CONCLUSIONS 
 The PVRM (Position, Velocity, and Resistance Meter) was used to evaluate the kinetic 
and kinematic data (angular position, velocity, and muscle resistance) during passive flexion and 
extension of healthy, spastic (MAS 1-4), and rigid (UPDRS 1-3) biceps and triceps at various 
stretch speeds. Key outcome parameters (e.g., range of motion, average and max stretch velocity, 
average and peak muscle resistance, difference in resistance at fast and slow stretch velocity, and 
catch presence) were computed from the raw PVRM data to provide a preliminary database 
quantifying spasticity and rigidity. This database can serve as a reference i) for understanding the 
abnormal muscle behaviors, ii) for optimizing designs of medical devices, and iii) for providing 
insight into developing algorithms for classifying spastic, rigid, and healthy muscles. Medical 
simulator development can benefit from this database to fine tune the simulators for more 
realistic replication of hypertonicity. Most importantly, the PVRM itself can serve as a clinical 
screening tool to reliably screen for the type and degree of hypertonicity without relying on 
subjective scales that require extensive training and experience.  
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CHAPTER 4: CONCLUSIONS 
4.1 REVIEW OF FINDINGS 
4.1.1 DESIGN AND VALIDATION STUDY OF THE PVRM  
In Chapter 2, we present a study where we designed and validated a portable custom 
measurement device (the PVRM – Position, Velocity, and Resistance Meter) that quantified 
abnormal muscle behaviors (i.e., spasticity and rigidity) of biceps and triceps in terms of kinetic 
and kinematic data during passive movement. The PVRM consisted of two modules (main and 
moving) and three surface electromyographic (sEMG) electrodes (biceps, triceps, and reference). 
The moving module was fastened on the participant’s wrist, while the main module was attached 
on the upper-arm. As a clinician applied force on the moving module to stretch the subject’s arm, 
the PVRM recorded the biomechanical data (i.e., angular position, speed, and force) during the 
passive movement. The data processing module computed the sampled time and biomechanical 
data from the main and moving modules and received the electromyographic (EMG) data from 
the electrodes.  
These PVRM modules were designed with three main design goals: 1) to provide 
accurate and reliable data describing muscle tone and movement of spastic and rigid arms, 2) to 
present an ergonomic and patient-friendly device that can be used in a clinical setting, and 3) to 
accommodate different geometries and sizes of muscles seen in both upper and lower 
extremities. To achieve the first design goal, we chose small inertial measurement units (IMU) to 
measure the kinematic data (angular position, speed, and acceleration), uniaxial load cell to 
evaluate the kinetic data (muscle resistance), and sEMG electrodes to monitor for voluntary 
muscle activity. For the second goal, miniaturized electronics and customized printed circuit 
boards were used to make the physical size of the PVRM smaller. In addition, the PVRM 
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transferred data wirelessly via Bluetooth module, removing the setup necessary for electrical 
cables. To accomplish the third goal, the main and moving modules of the PVRM contained a 
Velcro strap that can be easily adjusted to different shapes and sizes of the muscle. Therefore, the 
PVRM can quantify muscles in not only upper-extremities but also lower-extremities as well. 
After the development of the PVRM, we conducted a validation study to verify the accuracy and 
reliability of its measurements and to receive design feedback from the clinicians and patients.  
The validation study confirmed the accuracy of the PVRM measurements by comparing it 
to measurements (angular position, speed, and applied torque) from a commercial dynamometer 
(i.e., Biodex), a gold standard for quantifying biomechanical data. The study tested subjects with 
upper-arm spasticity (n=3), rigidity (n=2), and healthy muscles (n=5). The dynamometer stretched 
the subject’s arm via a custom-fabricated lever arm. The moving module of the PVRM was secured 
to the end of the lever arm, allowing the PVRM to measure the same kinetic and kinematic data 
measured from the Biodex dynamometer. The PVRM measurements were similar to the gold 
standard Biodex measurements during the passive flexion movement, since the residuals for all 
measurements were between 1-13%. The angular position and angular speed measurements of the 
PVRM were observed to be sufficiently accurate for quantifying kinematic behavior of all subject 
categories and even at high stretch speeds. While the torque measurement was the least accurate 
compared to angular position and speed measurement, it was still accurate enough to be used in 
quantifying unique kinetic behavior of hypertonicity: 1) elevated tone and a distinct increase of 
muscle tone (i.e., catch) seen from spastic muscle, and 2) uniformly elevated tone without a sharp 
increase in tone displayed by rigid muscles. Therefore, the PVRM was able to quantify behavioral 
features of spasticity (e.g., catch-release behavior), rigidity (e.g., uniformly elevated muscle tone), 
and healthy (e.g., no muscle resistance) subjects. 
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4.1.2 CLINICAL STUDY USING THE PVRM  
In Chapter 3, we present a clinical study using the validated PVRM to establish a 
preliminary database quantifying different levels of spastic and rigid arms during passive flexion 
and extension. Thirty-eight subjects with different levels of spasticity (n=15, MAS 1-4), rigidity 
(n=11, UPDRS 1-3), as well as gender-age matched healthy controls (n=12) were tested. A 
neurologist (CMZ) performed multiple stretches of the subject arm at four different stretch 
speeds (slow (5˚/s - 20˚/s), medium (20˚/s - 80˚/s), fast (> 80˚/s), and clinician’s preferred speed 
(> 30˚/s)) while the subject wore the PVRM modules and EMG electrodes.  
Key outcome parameters that quantify the unique muscle behaviors of spasticity and 
rigidity, (e.g., increased muscle tone, stretch speed dependency, presence of catch) were defined 
and analyzed. Spasticity subjects demonstrated stretch speed and MAS score dependent 
hypertonia marked by catch-release behavior, resulting in a convex parabolic stretch speed 
profile. Interestingly, catch-release behavior was only observed for approximately half the test 
trials, and the frequency of catch was higher for more severe spasticity subjects. As expected, 
catch-release behavior was triggered mostly at fast and preferred stretch speeds. Also, severe 
spasticity subjects (MAS 3, 4) had permanent muscle contractures that enhanced hypertonia and 
limited the range of motion. Rigidity subjects exhibited uniformly elevated muscle tone that was 
dependent on UPDRS score. The stretch speed dependency of rigidity differed based on the type 
of movement. Rigidity was slightly positively stretch speed dependent during extension, but 
negatively stretch speed dependent during flexion.  
We investigated the underlying pathophysiological mechanisms to explain these 
behavioral features of spasticity and rigidity by referencing past studies that examined the stretch 
reflex thresholds of hypertonicity [28,45,46,123–125]. For patients with hypertonicity, the range 
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of spatial threshold of stretch reflex fell within the biomechanical range of the moving limb, 
causing a motor deficit. This motor deficit can be identified as spasticity and rigidity. Further 
studies involving the stretch reflex activity and biomechanical behavior will be necessary to 
verify the pathophysiological mechanisms of hypertonicity. 
For spasticity trials, a few cases of unexpected muscle behavior were observed including 
1) excessive releases after catch during flexion trials, and 2) resemblance between spasticity 
without catch and rigidity in terms of kinetic behavior. For rigidity trials, excessive torque was 
sometimes applied at the start of the range of motion due to tilting of the load cell. Other times, 
the resistance increased linearly to joint angle, and the slope of this resistance profile was 
proportional to the UPDRS score. However, these irregular muscle behaviors happened in only a 
small percentage of the test trials. 
Some of the key outcome parameters can differentiate not only the type but also the 
severity of the hypertonicity. For example, parameters relating to muscle tone 
(𝜏𝑎𝑣𝑔, 𝜏𝑚𝑎𝑥, 𝑆𝑎𝑣𝑔, 𝑆𝑚𝑎𝑥, 𝑆𝑠𝑡𝑑 , 𝐸𝑛𝑜𝑟𝑚) can distinguish spastic and rigid muscles from healthy 
muscles, and parameters describing the stretch speed dependency of tone (i.e., SSD) can separate 
spasticity from rigidity. In addition, the magnitudes of these parameters can classify different 
levels of hypertonicity. For example, MAS scores are proportional to SSD, and UDPRS scores 
are proportional to parameters relating to muscle tone. Classifying the type and severity of 
hypertonicity can be beneficial to clinicians and patients for identifying and monitoring the 
progression of the underlying neurological disorder. Although qualitative scales such as the 
Modified Ashworth Scale (MAS) are used currently for this purpose, inexperienced clinicians 
have difficulty reliably assessing hypertonicity using these scales due to the heavy reliance on 
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the rater’s personal experience and interpretation of the scales. Therefore, the key outcome 
parameters presented in this study can potentially help the medical community by providing a 
new quantitative scale established from the PVRM data collected in future studies. Also, the 
PVRM can be optimized to automatically output a MAS or UPDRS score after a clinical 
assessment, alleviating clinicians from the burden of relying on past training experiences and 
subjective interpretation of the qualitative scales.   
 
4.2 FUTURE WORK 
The PVRM hardware design needs more iterations to provide better ergonomics and 
improved user-experience for the clinician and the patient. The usability of the PVRM can be 
enhanced by changing the uniaxial load cell with a 6-axis load cell sensor that can decouple any 
unwanted force and torque applied, allowing the rater to freely apply the load in multiple 
direction to the moving module. Thus, raters can still use their own assessment techniques 
without significant changes when using the PVRM during assessments of hypertonicity. In 
addition, the system of the PVRM can be simplified into a single module that collects, processes, 
stores, and transmits the PVRM and patient data. The EMG electrodes may be omitted in the 
future versions of the PVRM due to the long setup time for accurate EMG recordings.  
The testing protocol of the PVRM also needs revision in the future studies. First, the 
MAS score should be reported for every trial since a few of the MAS subject’s score changed 
during every test trial. These score changes could be attributed to not only the loosening of 
muscles due to frequent passive movements, but also other factors such as the stress level of the 
subject and inherently fluctuating nature of hypertonicity [1,3]. Second, the arm posture during 
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flexion test trials should be similar during extension test trials. In our study, the arm position 
during flexion was approximately perpendicular to the ground, while the arm position during 
extension was almost parallel to the ground. For practical clinical use and more direct 
comparison of data, flexion and extension should involve a similar movement plane relative to 
the ground. Third, stretch speed for each test trial should be randomized instead of being 
sequential. Since hypertonia arising from spasticity and rigidity may change after numerous 
stretches of the muscle, the torque data collected near the end of test trials (i.e. fast and preferred 
stretch speeds) may be downscaled in our study.  
We still suggest future studies with more test subjects and raters, since we only tested 
three subjects per level of spasticity and rigidity. Additional subjects must be recruited to 
comprehensively represent the patient population to perform more reliable statistical analysis on 
the quantitative differences between spasticity and rigidity. We recommend that at least fifteen 
subjects be recruited for each level of MAS and UPDRS. In addition, more raters with varying 
level of relevant clinical experience should be involved to determine if the PVRM can reproduce 
repeatable results regardless of the rater’s previous experience. Another potential future study 
can be the investigation of hypertonicity for lower extremities, since hypertonicity about the 
ankles and knees are common [130,131]. After optimizing the PVRM hardware design as 
mentioned above, the PVRM modules can be easily implemented for various muscle groups. 
Other possible studies may include quantifying the effect of treatments for spasticity (e.g., 
baclofen and Botox injections) and rigidity (e.g., deep brain stimulation and levodopa) using the 
PVRM [138,139]. Selecting the proper dosage and timing for these medications is important to 
minimize the side effects [138]. For example, too much dosage of baclofen may cause excessive 
weakening of muscles and tiredness, while too little dosage may not help with reducing 
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spasticity [138]. The PVRM can help with not only quantifying the efficacy of these treatments, 
but also providing the clinicians and patients with a proper dosage of medications for effective 
and safe treatment.  
In the long-term future, the author envisions extensive use of technology quantifying the 
symptoms of neurological disorders in the clinical setting for more accurate and reliable 
assessments. The two problems faced in the field of neurology are the shortage of neurologists 
and the difficulty of screening for neurological disorders in the early stages of development. In 
2012, the shortage of neurologists was 11% and is expected to grow to 19% by 2025 [140]. 
According to Vidic et al., “In the absence of efforts to increase the number of neurology 
professionals and retain the existing workforce, current national and geographic shortfalls of 
neurologists are likely to worsen, exacerbating long wait times and reducing access to care for 
Medicaid beneficiaries. Current geographic differences in adequacy of supply likely will persist 
into the future.” [140]. Also, many motor and non-motor symptoms of neurological disorders are 
often ambiguous, making the screening process difficult and subjective. For example, the motor 
and non-motor section (e.g., tremor, gait, posture, hand movements, facial expressions, 
handwriting, motivation, speech, salivation) of the Unified Parkinson’s Disease Rating Scale 
(UPDRS) all rely on subjective interpretation of the scales, since qualitative words such as 
“mildly affected” and “severely affected” are used to describe different levels of rigidity. With 
the advent of cost-effective sensors and advanced algorithms, these motor and non-motor 
symptoms are quantifiable [141,142]. For example, a camera can record the facial expressions, 
gait, and posture of the PD patients and look for traits of distinct PD [142]. Given a large 
database of speech patterns from PD patients, machine learning algorithms can be implemented 
to screen for PD from audio data collected via a microphone [141].  
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I predict that patients in the future can be diagnosed in a room equipped with quantifying 
devices (e.g., cameras, microphones, PVRM’s) that objectively evaluate patient’s behaviors 
related to motor and non-motor symptoms (e.g., gait, posture, speech, rigidity). The patient will 
follow a set of instructions (e.g., walking/running on a straight path or reading a sentence 
displayed on a screen) with a help of a nurse or general practitioner while the devices record the 
patient’s behaviors. If the patient exhibited distinctive signs of PD or other neurological 
disorders, he or she can be referred to a neurologist nearby. Hence, the patient can not only be 
screened earlier for neurological disorders but also the chances of misdiagnosis can be reduced 
with the use of these technologies, alleviating the neurologist’s burden while providing the 
patients with more available and standardized diagnosis [117,141–143]. Developing this 
technology will require extensive interdisciplinary collaboration including fields such as 
neurology, computer science, and engineering in order to fuse the ample data collected from 
various sensors together and process the multidimensional data to accurately diagnose the 
patient. Thus, the research of the PVRM should be conducted in conjunction with other emerging 
technologies to strive for convenient but accurate diagnosis that benefit patients and clinicians.  
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APPENDIX A: SUPPLEMENTARY FIGURES AND RESULTS FOR VALIDATION 
STUDY 
 
Figure A.1. Comparison between the PVRM and Biodex data during a full trial (left column) and constant 
flexion speed (right column) for a control subject (C4) during flexion (a, b) at 75˚/s, and (c, d) at 45˚/s. The 
constant flexion-speed-region (vertical dashed lines) in full trial plots was extracted. 
(a) 
Full trial Constant Flexion Speed 
(b) 
(d) (c) 
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APPENDIX B: ESTIMATING MASS, CENTER OF MASS LOCATION, AND MOMENT 
OF INERTIA OF LOWER ARM  
The effect of gravity and inertia of the lower arm (forearm and wrist) had to be removed from the 
PVRM torque data to analyze just the muscle resistance due to spasticity or rigidity. To do so, 
the mass (M), center of mass length (Lcom), and moment of inertia (I) about the elbow was 
estimated using empirical anthropometric equations and simple static equations shown below 
[101].  
 
𝑀 (𝑘𝑔) = 𝑏𝑜𝑑𝑦 𝑚𝑎𝑠𝑠 (𝑘𝑔) ×
𝑃𝑔𝑒𝑛𝑑𝑒𝑟(%)
100
   {
𝑃𝑔𝑒𝑛𝑑𝑒𝑟 = 2.52 , 𝑖𝑓 𝑔𝑒𝑛𝑑𝑒𝑟 = 𝑚𝑎𝑙𝑒
    𝑃𝑔𝑒𝑛𝑑𝑒𝑟 = 2.07, 𝑖𝑓 𝑔𝑒𝑛𝑑𝑒𝑟 = 𝑓𝑒𝑚𝑎𝑙𝑒
 
𝐿𝐶𝑂𝑀 (𝑚) = 0.652 × 𝑓𝑜𝑟𝑒𝑎𝑟𝑚 𝑙𝑒𝑛𝑔𝑡ℎ(𝑚) 
COM length was defined as the distance from the elbow epicondyle along the ulna bone. 
 
𝐼 (𝑘𝑔 ∗ 𝑚2) = 𝐼𝑐𝑒𝑛𝑡𝑟𝑜𝑖𝑑 + 𝑀𝐿𝐶𝑂𝑀
2 =
1
3
𝑀𝐿𝑙𝑜𝑤𝑒𝑟−𝑎𝑟𝑚 𝑙𝑒𝑛𝑔𝑡ℎ
2 + 𝑀𝐿𝐶𝑂𝑀
2  
Moment of inertia was about the rotation axis of the elbow joint which was obtained through 
parallel axis theorem. The moment of inertia of the lower-arm (forearm and wrist) about its 
centroid (𝐼𝑐𝑒𝑛𝑡𝑟𝑜𝑖𝑑) was simplified as a rod with lower-arm length and lower-arm mass, rotating 
about one end. 
 
 
 
109 
 
APPENDIX C: INSTITUTIONAL REVIEW BOARD (IRB) APPROVAL LETTERS 
FROM UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN (UIUC) AND 
UNIVERSITY OF ILLINOIS COLLEGE OF MEDICINE AT PEORIA (UICOMP) 
 
Figure C.1. Institutional Review Board (IRB) approval letter from University of Illinois at Urbana-
Champaign (UIUC) IRB 
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Figure C.2. Institutional Review Board (IRB) approval letter from University of Illinois College of 
Medicine at Peoria (UICOMP) IRB. The UICOMP’s IRB approval allowed us to conduct testing at Bradley 
University, Peoria IL.  
